ࡱ> O jbjbj&& MgLegLe^jj$P#|T>v pyyy[$V$$uuuuuuu$x{"u$#@#^$$uyyDuS.S.S.$^yyuS.$uS.S.ioy0 ̠;%k6uv0>k|%|oo8|o$$.$$$$$uu*<$$$>v$$$$|$$$$$$$$$j u:  ROSSINI 2: Reduction Of Surgical Site Infection using several Novel Interventions A phase III, multi-arm, multi-stage (MAMS), pragmatic, blinded (patient and outcome assessor), multicentre, randomised controlled trial (RCT) with an internal pilot, to evaluate the use of several in-theatre interventions, used alone or in combination, to reduce SSI rates in patients undergoing abdominal surgery. SUMMARY INFORMATION SHEET Version 4.0, 12th July 2022 Summary of invitation to take part in the research trial ROSSINI 2. Your surgeon has recommended you undergo an operation on your abdomen (tummy). As with any operation, this carries a risk of developing an infection in the cut/ incision (also called a Surgical Site Infection or SSI) This hospital is taking part in a research trial called ROSSINI 2, which aims to find out whether using three different changes to the normal treatment plan (referred to as interventions), used either separately or in combination, during your operation can reduce the chances of a patient developing an infection. It is possible that these interventions might have a combined effect. Our trial will test each method and look in a logical fashion at how they might work together. This multi-arm, multi-stage (MAMS) trial has the opportunity to drop (e.g. combinations showing a lack of benefit) and introduce (e.g. combinations based on new, available evidence) interventions at specified time points. MAMS trials aim to answer multiple questions simultaneously within one trial. The in-theatre interventions being investigated at present are: An alcohol-based skin preparation (a cleansing solution for skin) An antibiotic-impregnated sponge (delivers antibiotics in wounds to kill bacteria locally). If you wish to participate in the trial, you will not get to decide which intervention(s) are used as you will be randomly allocated to receive all, some, one, or none of these interventions. Patients that receive an intervention will form one group, and will be compared to a control group who will undergo their operation in the normal way where no trial intervention is used. All patients will have their wounds assessed by a doctor or nurse who is unaware of whether an intervention was used, to see if an infection has developed after their operation. You do not have to take part in ROSSINI 2, and if you decide not to, no-one will think badly of you and this will not affect the quality of your care in any way. If you are interested in finding out more about this trial, please continue to read the Patient Information Sheet.  ROSSINI 2: Reduction Of Surgical Site Infection using several Novel Interventions A phase III, multi-arm, multi-stage (MAMS), pragmatic, blinded (patient and outcome assessor), multicentre, randomised controlled trial (RCT) with an internal pilot, to evaluate the use of several in-theatre interventions, used alone or in combination, to reduce SSI rates in patients undergoing abdominal surgery. PATIENT INFORMATION SHEET Version 4.0, 12th July 2022 We would like to invite you to take part in the ROSSINI 2 research trial. Joining the trial is entirely up to you. Before you decide, we would like you to understand why the research is being done and what it will involve for you. A member of our research team will go through this information sheet with you, to help you to decide whether or not you would like to take part and to answer any questions you may have. Please feel free to talk to others about the trial if you wish. Part 1 of this Patient Information Sheet (PIS) tells you the purpose of the trial. Part 2 gives more detailed information about what will happen to you if you take part and about the conduct of the trial. Please do take the opportunity to ask any questions you have and to ask for more information if anything is unclear. Part 1 What is the purpose of the ROSSINI 2 trial? ROSSINI 2 stands for Reduction Of Surgical Site Infection using several Novel Interventions 2. The overall aim is to see if using different interventions during abdominal (tummy) surgery will reduce the chance of you getting a surgical site infection. What is a Surgical Site Infection (SSI)? How common is it? A surgical site infection (SSI) is an infection of the incision (cut) made by your surgeon through which the operation is performed. It is also commonly called a wound infection. The chances of developing an infection vary according to many factors. Some of these are dependent on you as the individual patient, for example if you smoke or suffer from diabetes your chances of developing an SSI are increased. Other factors include the length of the operation, the exact nature of the surgery and whether it is performed as an emergency or a planned procedure. After abdominal surgery, around one in seven patients will develop an SSI, This rate can increase to one in three if the operation is an emergency. What are the consequences of developing a Surgical Site Infection (SSI)? The main problem that patients experience if they develop an infection in their wound is that it takes longer to fully recover and heal. This means they may experience more pain and discomfort than they normally would and this could result in them staying in hospital longer and probably requiring a course of antibiotics. Very occasionally patients need another operation or procedure to deal with a wound infection. In some patients a wound that becomes infected can produce a less tidy scar. Who is organising and funding the research? The ROSSINI 2 trial was developed by the West Midlands Research Collaborative, and is funded by the Health Technology Assessment programme of the NHS research funding charity, the National Institute for Health Research (NIHR). The trial is coordinated by the ROSSINI 2 trial office at University 鶹ѡ, Birmingham Clinical Trials Unit (BCTU). What are the interventions being tested in the Operating Theatre? If you choose to take part in the trial, at present you will be randomly selected to receive different interventions or be in the control group. If you are randomised to the control group, this means you will receive a skin preparation and/or any other intervention that your surgeon would normally use but it will not be any of the specific interventions we are currently looking at in the trial. All interventions used in the trial may be tested alone or in combination. They are all interventions which are already used by some surgeons in the NHS, but lack the evidence required to be used for every patient undergoing surgery. We are testing these interventions in different combinations because it is possible that they might have a combined effect. The trial will test each intervention and look at how they might work together. Please remember that this is a MAMS trial which means that we may drop (or introduce) certain combinations of treatments or even whole interventions at specified time points within the trial. We may even introduce new combinations or interventions at short notice, but a member of the research team will always discuss this with you. The interventions currently being investigated are: Chlorhexidine 2% alcohol skin preparation is a cleaning solution to cleanse and sterilise the skin before surgery. This is being compared against any other standard skin preparation normally used. Gentamicin-impregnated collagen sponge - small absorbable sponges placed in the wound at the end of the operation that slowly dissolve and disappear over time whilst delivering antibiotics in to the wound to try and kill any bacteria present that may go on to cause an SSI. This is being compared against no sponge. What are the possible disadvantages and risk of these interventions? To the best of our knowledge the additional interventions do not add any further risk to your operation itself. The skin preparation takes approximately two to three minutes to apply at the start of the operation. The sponges are left in the wound at the end of the operation and take approximately five minutes to insert. As with any intervention, there is a rare risk of allergy. If you have a documented or suspected allergy to any of the interventions (or its parts) we will not offer you that intervention but you can still participate in the trial. What are the possible benefits of taking part in ROSSINI 2? These all have the potential benefit of reducing the chances of you developing an infection in the wound. The alternative possibility is that the interventions will not be of any benefit at all. To the best of our knowledge, none of the included interventions will increase your risk of getting a SSI. Why are these interventions not used during operations routinely if there is a possibility that they may help reduce infections? Whilst skin preparation is routinely used in all operations, we do not know for definite if these interventions are an improvement on current surgical practice. There have been some similar (although smaller) studies of these interventions which showed encouraging results with decreased rates of infection in patients. However, the studies did not involve enough patients to allow us to recommend that these interventions (alone, or in combination) be used in all patients undergoing abdominal surgery. Although the interventions are not too expensive, they still add an additional cost to the NHS and we have to be sure that they offer some benefit before starting to use them routinely in everyone across the country. How have patients and the public been involved in this Trial? A group consisting of patients and members of the public helped to develop this research topic and the research questions that should be asked. In designing this trial, we have considered patient opinions on the frequency of participant visits and any tests that we will carry out. Potential participants were involved in reviewing the Participant Information Sheet and Informed Consent Form, and deciding on the inclusion and exclusion criteria for people taking part in this trial. Part 2 Why have I been chosen? The consultant surgeon in charge of your care is involved in the ROSSINI 2 trial as they feel the trial asks an important question. As such they are inviting all of their patients who are planned to undergo an operation on the abdomen to take part in ROSSINI 2. Your surgeon thinks that taking part in ROSSINI 2 would be a good option to help find out if these interventions work or not. ROSSINI 2 will include over 6600 people like you from hospitals throughout the UK. What would taking part in ROSSINI 2 involve? If you agree to participate in the trial you will be asked to complete extra questionnaires regarding your wound and its healing as well as information about how you are feeling at various stages throughout your treatment. These details about you will be collected at baseline, before you go home and 30 days after your operation. The local trial investigator(s) will also record some additional information about your medical history and exact operation details. The central part of your involvement in the trial will occur when you are anaesthetised (asleep) for your operation. At this stage we shall contact the Centre for Healthcare Randomised Trials (CHaRT) at The Institute of Applied Health Sciences at University of Aberdeen who will tell us which intervention(s) (if any) to use. After the operation, regardless of which group you were in, the follow-up will be the same. This shall take the form of two formal reviews of your wound to check its healing and assess for any signs of a wound infection. These shall be performed by a doctor, specialist nurse or another trained individual who is not aware which intervention(s) were used in theatre. The first of these reviews will occur before you go home after the operation. The second will be at around 30 days after your surgery. This will either require you to return to hospital or be contacted remotely via a video call or the telephone. This assessment will usually be combined with your routine review after surgery. You will not be reimbursed for any travel costs if you do return to hospital. After this 30-day review, your involvement in the ROSSINI 2 trial will normally be complete. On the rare occasion that your infection has not resolved by 30 days after surgery, we (at the hospital or from Birmingham Clinical Trials Unit) will continue to contact you via telephone or post for review via questionnaires every 30 days until your wound has healed. Do I have to take part? No. Taking part in research is always voluntary. If you decide to take part you will be asked to sign a consent form but you are still free to withdraw at any time and without giving a reason. If you decide not to take part, you dont have to give any reason why and no-one will think badly of you for not wishing to take part. Your care will not be affected in any way. Your surgeon or local trial investigator will be happy to talk through any questions you may have regarding ROSSINI 2. What will happen if I dont want to carry on with the trial? You can decide not to continue with follow-up at any time but, if you do, we would still like your data to remain on file and be included in the trial analysis unless you specifically ask to be excluded. Can I pick which intervention(s) the surgeon uses? So that we can find out which intervention(s) are best, the intervention that you receive will be decided for you by a process called randomisation. This gives you roughly the same chance of receiving any one of the intervention(s) or none at all. Neither you nor your surgeon can choose which intervention you receive. This is essential so that a fair comparison can be made between the groups and that characteristics such as age or operation type is the same for all intervention(s). Dividing people into groups in this way is what is called a randomised clinical trial and is the standard and most reliable way of comparing different treatment options. Bovine collagen is a material within the Gentamicin-impregnated collagen sponge. It comes from treated cow hides as a by-product of the meat industry. Such products are widely used in health care products. Should you not wish to be randomised to receive this intervention then you cannot enter the trial. Who will know which intervention(s)/group I received? Only the surgeon and the team in theatre will be aware of which group you are in and which intervention(s) were used during your operation. The other doctors involved in your care, as well as the ward nurses and your GP will know that you participated in the trial but not which group were allocated to. There will be no direct mention of this in your hospital notes other than that you are included in the trial. It is important to maintain this secrecy so that when your wound is assessed after the operation, we (and you) are not swayed by knowing if a particular intervention(s) were used during your surgery. This is called blinding of research. Emergency unblinding will only be permitted for medical reasons (e.g. severe allergy), and would be coordinated by the BCTU Trials Office. Can I ever find out which intervention(s)/group I received? Yes Only upon request, at the end of the trial, once the final patient has completed 30-day follow-up and the database is closed will patients be told which group they were allocated to. For safety, if at any time there is a concern about your care which means that a doctor needs to know which intervention(s) were used, they can contact the trial coordinating unit who will be able to discuss this with them and let them know which intervention(s) were used. What if small changes are made to the trial or new information becomes available? Sometimes we get new information about one of the interventions being studied. If this happens, your surgeon will discuss how this affects your care and your ongoing participation in the ROSSINI 2 trial, if needed. You and your surgeon should consider whether you wish to continue in the trial or withdraw. Either way, your surgeon will explain the changes and all other aspects of your care will continue as normal. If you decide to continue in the trial you may be asked to sign an updated consent form. If the trial is stopped for any other reason, your surgeon would, again, tell you and arrange your continuing care. What if something goes wrong? What if I get a Surgical Site Infection (SSI)? It is always possible to develop an SSI after an operation and we cannot guarantee that you will not get one, regardless of whether or not you participate in the ROSSINI 2 trial. If you do have a SSI, we will administer all standard care as appropriate. If you have a concern about any aspect of this trial, you should ask to speak to a member of the research team who will do their best to answer your questions. If you remain unhappy and wish to complain formally, you can do this by contacting . Details can be obtained from . Will my taking part in ROSSINI 2 increase my chances of catching SARS-CoV-2 / Coronavirus / Covid-19? There is no increased risk of catching the SARS-CoV-2 virus (also called Coronavirus, which can sometimes develop into Covid-19 disease) from participating in the ROSSINI 2 trial. The interventions we are assessing in the trial do not increase your risk or your potential exposure to the virus before, during or after your operation. The trial mirrors your hospitals standard pathways and the follow-up assessments are timed to coincide with routine clinical follow-up appointments. If you are not able to return to hospital in person for a post-operative visit, for example due to current hospital policies to try and limit movement on hospital sites, the review of your wound can be undertaken remotely via a video consultation or on the telephone. Whether you enter the ROSSINI 2 trial or not, your hospital may have routine pre-operative preparation pathways, including self-isolation or swabbing policies which all patients need to adhere to prior to surgery - these will not be affected in any way by participation in the trial. Will my taking part in ROSSINI 2 be kept confidential? If you decide to take part in ROSSINI 2, we will need to collect information about you and some of this information will be your personal data. Under data protection law, we have to provide you with very specific information about what we do with your data and about your rights. The University 鶹ѡ is the sponsor for this trial based in the United Kingdom. The University will use information from you and your medical records and will act as the data controller for this trial. This means that the University 鶹ѡ is responsible for looking after your information and using it properly. Your rights to access, change or move your information are limited, as we need to manage your information in specific ways in order for the research to be reliable and accurate. If you withdraw from the trial, we will keep the information about you that we have already obtained. To safeguard your rights, we will use the minimum personally-identifiable information possible. More information on how the University processes personal data can be found on the Universitys website on the page Data Protection How the University Uses Your Data ( HYPERLINK "http://www.birmingham.ac.uk/privacy/indec.aspx" http://www.birmingham.ac.uk/privacy/indec.aspx). Your hospital will use your name, NHS number, date of birth and contact details to contact you about the ROSSINI 2 trial, and make sure that relevant information about the trial is recorded for your care, and to oversee the quality of the trial. Individuals from The University 鶹ѡ and regulatory organisations may look at your medical and research records to check the accuracy of the research trial. Your hospital will pass these details to the University 鶹ѡ along with the information collected from you and your medical records. The only people at the University 鶹ѡ who will have access to information that identifies you will be people who need to contact you to complete questionnaires or audit the data collection process. The people who analyse the information will not be able to identify you and will not be able to find out your name, NHS number or contact details. Your hospital and the University 鶹ѡ will keep identifiable information about you from this trial for 10 years after the trial has finished. Your GP and the other doctors involved in your clinical care will also be notified of your participation in the ROSSINI 2 trial and kept informed of your progress. Also, the research staff involved in the trial may, in the future, access electronic data from your central NHS records, for example through NHS Digital. This will provide researchers with information that is routinely gathered and stored during your visits to primary care and hospital, and will allow researchers to find out about your health after the trial has ended and the long-term effects of the treatments. By using routinely collected data we will be able to do this without needing to contact you further. In order to do this, we would need to send your name, gender, date of birth and NHS number with any request for information. The University takes great care to ensure that personal data is handled, stored and disposed of confidentially and securely. Our staff receive regular data protection training and the University has put in place organisational and technical measure so that personal data is processed in accordance with the data protection principles set out in data protection law. With regards to ROSSINI 2, information about your operation and follow-up will be sent by your doctors to the ROSSINI 2 Trial office at the Birmingham Clinical Trials Unit (BCTU), University 鶹ѡ on paper and/or electronically, where it will be securely stored. Under data protection law, the legal basis we have to process your personal data is that it is necessary for this research, which is carried out in the public interest. This data will not be used to make decisions about your clinical care. The manufacturers of all the interventions for the trial will review limited information about any complications experienced by anyone in ROSSINI 2. This data will be anonymised and will not identify you. What will happen to the results of the trial? Once ROSSINI 2 has finished we will publish the results in a medical journal so that other patients can benefit. We will also publicise the results on the trials website www.birmingham.ac.uk/ROSSINI2. No individual patients will be identifiable in any publications. A copy of the published results of the trial will be sent to all patients who have participated in ROSSINI 2. In line with clinical trial guidelines, at the end of the trial, the data will need to be securely archived for a minimum of 10 years. Arrangements for confidential destruction will then be made. Should you withdraw consent for your data to be used, it will be confidentially destroyed at that point. Who has reviewed the trial? All research in the NHS is reviewed by an independent group of people called the Research Ethics Committee to ensure your safety, rights, wellbeing and dignity. This trial has been reviewed and given favourable opinion by Wales REC 6 Research Ethics Committee. Where can I get further information? If you have any further questions about your operation or this clinical trial, please discuss them with your surgeon or local trial investigator, as below: Name: ...................................................................................................... Tel No: ....................................................................................................... Position: ....................................................................................................... Thank you for taking the time to read this Patient Information Sheet.     _____________________________________________________________________________________  Patient Information Sheet (IRAS TRIAL ID: 247285) Version 4.0, 12th July 2022 Page  PAGE \* Arabic \* MERGEFORMAT 10 of  NUMPAGES \* Arabic \* MERGEFORMAT 10 _____________________________________________________________________________________  Patient Information Sheet (IRAS STUDY ID: 247285) Version 2.0, 24th January 2019 Page  PAGE \* Arabic \* MERGEFORMAT 2 of  NUMPAGES \* Arabic \* MERGEFORMAT 10 _____________________________________________________________________________________ ______________________________________________________________________________  Patient Information Sheet (IRAS STUDY ID: 247285) Version 2.0, 24th January 2019 Page  PAGE \* Arabic \* MERGEFORMAT 3 of  NUMPAGES \* Arabic \* MERGEFORMAT 10   ʶq_qH0/hJh^5B*CJOJQJ]^JaJ$ph,hJh^5B*CJOJQJ^JaJ$ph#hCHNh5CJOJQJ^JaJ,hCHNh5B*CJOJQJ^JaJph$,hCHNh5B*CJOJQJ^JaJphN,hh5B*CJOJQJ^JaJphN&hQ5B*CJOJQJ^JaJphN&hQ5B*CJ OJQJ^JaJphN&hQ5B*CJOJQJ^JaJphNjhQUmHnHu X  % & ^`gdW& & F^`gdW& & F^`gdW&gd^$a$gd^ $ a$gd^$a$gdT#$a$gd^L$a$gd<0'(,-DEJKWXZ[   7 < 麤~hU%h&~6B*OJPJQJ]^Jph+hT#h6B*OJPJQJ]^Jph%h6B*OJPJQJ]^Jph%h 6B*OJPJQJ]^Jph+hT#hT#6B*OJPJQJ]^Jph,hoh^5B*CJOJQJ^JaJ$ph/hJh^5B*CJOJQJ]^JaJ$ph,hJh^B*CJOJQJ]^JaJ$ph  ǸwhYG7*h&~5OJQJ^JaJh#h^5OJQJ^JaJ#h#h^5CJOJQJ^JaJh^5CJOJQJ^JaJhl5CJOJQJ^JaJhW5CJOJQJ^JaJ&hWhW5CJH*OJQJ^JaJh5CJOJQJ^JaJh(m|5CJOJQJ^JaJh\#5CJOJQJ^JaJh,+5CJOJQJ^JaJh^5CJOJQJ^JaJ3hT#hT#56B*CJ OJPJQJ^JaJ$ph_Iz       ! # & ( ) * a %   % A E F O W c žɭɌɌɈɁ}vohahvhvhahvav}va h\#h\# h\#h h\#ht h\#h#.&h\# h\#h^h..h$ghwh5CJaJ hwh5B*CJaJph$ hwh5B*CJaJphN h#h"h" h#h^h#h^OJQJ^JaJh#h^5OJQJ^JaJh#h&~5OJQJ^JaJ&  .9=>?@JPQacde)AHz*5QSXY[˺˳˨~z~v~~r~kghs hChs h%h"hQI hChWn h^LhWnh^LhWnaJh1ohWn5h$g h1ohWnhWn h\#h.. h\#h9hl~hWn5\ h\#h$g h\#hWnh&~ h\#hY h\#hz h\#ht h\#h^ h\#h h#h\#% @Z['()*+,$a$gd^L$a$gd<0 & FV^`Vgd\#  & F^gd\# & Fgd\# & F^`gd\# & F^`gdW& & F^`gdW&[ /14678'CDҵ㬘qaqQq=&hEQ5B*CJOJQJ^JaJphNhs 5B*OJQJ^JphhTrV5B*OJQJ^Jph$hcthTrV5B*OJQJ^Jph&h'5B*CJOJQJ^JaJphN&h^5B*CJOJQJ^JaJphNh#h^CJhwhs 5CJaJ hwhs 5B*CJaJph$ hwhs 5B*CJaJphN h#h^ h#h..h$ghs h#hs ,-./0123456789:;<=>?巡$$<0DEGHJMOPQST]̵u^F/,h~Xh{&HB*CJOJQJ]^JaJ$ph/hlh{&H5B*CJOJQJ]^JaJ$ph,hlh{&H5B*CJOJQJ^JaJ$ph#hCHNh5CJOJQJ^JaJ,hCHNh5B*CJOJQJ^JaJph$,hCHNh5B*CJOJQJ^JaJphN,h9hEQ5B*CJ(OJQJ^JaJ(phN&hy5B*CJOJQJ^JaJphN>jhEQ5B*CJOJQJU^JaJmHnHphNtH u ]^`aijnoWиrrr[E2E2E%h 6B*OJPJQJ]^Jph+hT#hT#6B*OJPJQJ]^Jph,hEQh{&H5B*CJOJQJ^JaJphN,hCHNh{&HB*CJOJQJ]^JaJ$ph/hCHNh{&H5B*CJOJQJ]^JaJ$ph,h h{&HB*CJOJQJ]^JaJ$ph/h h{&H5B*CJOJQJ]^JaJ$ph,h~Xh{&HB*CJOJQJ]^JaJ$ph/h~Xh{&H5B*CJOJQJ]^JaJ$phH  129:fdeUhi $a$gd: $xa$gdzS$ dha$gdT#$a$gd(m| $ a$gd<0$a$gdT#$a$gdEQW_y~  ֩yjy[G8)h(m|5CJOJQJ^JaJhW5CJOJQJ^JaJ&hWhW5CJH*OJQJ^JaJh5CJOJQJ^JaJhW&5CJOJQJ^JaJht5CJOJQJ^JaJh6*5CJOJQJ^JaJ#hCHNh{&H5CJOJQJ^JaJ3hT#hT#56B*CJ OJPJQJ^JaJ$ph_Iz%hif6B*OJPJQJ]^Jph+hT#hT#6B*OJPJQJ]^Jph%h6B*OJPJQJ]^Jph  <>ACDEFOTbh;@1289:ͺͬxdPChzSh5HuOJQJ^J'hzSh65>*B*OJQJ^Jph'hzSh5>*B*OJQJ^JphhzSh6OJQJ^JhzShOJQJ^JhzShOJQJ^JhzShOJQJ^JhzSh5OJQJ^J$hzSh5B*OJQJ^Jph$$hzSh5B*OJQJ^JphNhzShGOJQJ^J#hT#hT#5CJOJQJ^JaJ:\^_dfhkmnop|}yjyjyjyjyjZyjyjyZyhzShYw0J5OJQJ^Jh:h0JOJQJ^JhzSh0J5OJQJ^JhzSh>OJQJ^JhzSh>5OJQJ^J$hzSh>5B*OJQJ^Jph$$hzSh>5B*OJQJ^JphN"hzSh0J5>*OJQJ^J"hzShYw0J5>*OJQJ^J"hzSh0J5>*OJQJ^J "=IcdeϿtgZgM@M3hzShCHNOJQJ^JhzSh2OJQJ^JhzSh(OJQJ^JhzShUOJQJ^JhzShOJQJ^JhzSh>*ϴ..ϴύ05Oϴ05Oϴ505OϴY05Oϴ205Oϴ󰭳05Oϴ05Oϴ'(,234#9<FJx̿椖̉̉̉|obobo|ob̉̉hzShKz`OJQJ^JhzShUOJQJ^JhzSh>ϴrϴ>*ϴ>*ϴ..ϴ(ϴϴ󾱴ڿϴᱷϴ2ϴ&̿ɋ~]<hYh65OJQJ^J$hYh65B*OJQJ^Jph$$hYh65B*OJQJ^JphNhYh>*OJQJ^JhYhOJQJ^JhYhOJQJ^JhNhOJQJ^Jh%yjhUOJQJ^Jh%yjha9OJQJ^Jh%yjhOJQJ^Jh%yjhOJQJ^JhzShr@OJQJ^JhzShKz`OJQJ^JhzShOJQJ^J-.p "$9$%<&=&&(((***,l-m-->../ $a$gdzS & FgdW& $xa$gdzS $a$gd:,-.3ƹƦxk^Q^D6h:h>*OJQJ^Jh:hJfOJQJ^Jh:hWe6OJQJ^Jh:hOJQJ^Jh:h[kfOJQJ^Jh:h6OJQJ^Jhhrh65OJQJ^J$hhrh65B*OJQJ^Jph$$hhrh65B*OJQJ^JphNhhrh|#OJQJ^JhhrhOJQJ^Jhzh|#OJQJ^Jhzh6OJQJ^J$hzh65B*OJQJ^Jph$3;HYhop    & ' I [ \ z  "!չxk^x^xxxQxQxxh:h2DOJQJ^Jh:h8!OJQJ^Jh:hnEOJQJ^Jh:h#OJQJ^Jh:h 4OJQJ^Jh:hIOJQJ^Jh:htOJQJ^Jh:hUOJQJ^Jh:h>*OJQJ^Jh:h2>*OJQJ^Jh:hU>*OJQJ^Jh:hKz`>*OJQJ^Jh:h>*OJQJ^J"!;!e!!! "$"g""""" #-#.#/######$$8$9$R$󿲫{naSh%yjh5OJQJ^Jh%yjhtOJQJ^Jh%yjhOJQJ^Jh%yjhmmgaJh%yjhaJh%yjhtaJ h%yjh h%yjhzS h%yjhmmg h%yjhth:hOJQJ^Jh:hYVOJQJ^Jh:h 7OJQJ^Jh:hUOJQJ^Jh:hKz`OJQJ^Jh:hOJQJ^JR$b$c$d$e$h$$$% %&%~%%%%%%%%&!&4&:&<&ƹ~qdWJ=hYhOJQJ^JhNhOJQJ^Jh%yjhOJQJ^Jh%yjhOJQJ^Jh%yjhcOJQJ^JhzSh(OJQJ^JhzShOJQJ^J$hzSh5B*OJQJ^Jph$hzSh5OJQJ^JhYhOJQJ^JhNhOJQJ^Jh%yjh(OJQJ^Jh%yjhOJQJ^J$h%yjh5B*OJQJ^Jph$<&=&m&s&&&&&&&&&&' ''''/'V'W''''ɻyl_lRHRl;_RHh:hOJQJ^Jh:OJQJ^Jh:hOJQJ^Jh:hKOJQJ^Jh:hIB[OJQJ^Jh:hOJQJ^JhhrhOJQJ^JhhrhIB[OJQJ^JhzhAHOJQJ^Jhzh>*OJQJ^JhYh>*OJQJ^JhYh 7>*ϴۚ>*ϴۚʳ>*ϴۚϴ''''''<(I((((((((|))))))))***ٿ||oboUo|UbUHh:hOJQJ^Jh:hgwOJQJ^Jh:h 7OJQJ^Jh:hOJQJ^Jh:hIB[OJQJ^Jh:hQ>*OJQJ^Jh:h~X>*OJQJ^Jh:hQOJQJ^Jh:hk/OJQJ^Jh:h~XOJQJ^Jh:hOJQJ^Jh:hKOJQJ^Jh:hOJQJ^Jh:h:OJQJ^J**(*5*?*Q*u*z******** + +:+z++++1,\,,,A-K-W-j-l---層}p}}}}}}bTh:h[kf>*OJQJ^Jh:h6>*OJQJ^Jh:hAHOJQJ^Jh:h2jOJQJ^Jh:h(vOJQJ^Jh:hOJQJ^Jh:h3OJQJ^Jh:h(OJQJ^Jhq>*OJQJ^Jh:h3>*OJQJ^Jh:h 7>*OJQJ^Jh:h>*OJQJ^Jh:hT#OJQJ^J --P.U.V.W._.i..../7/:/;/G//////////佰{gYK>h:hOJQJ^Jh:h>*OJQJ^Jh:h 7>*ϴ':5>**ϴ$':5>**ϴ$'::5>**ϴ$:ϴ:#ϴ:ϴ:ϴ:Jϴ:6ϴ:6>*ϴ////111<9=9U9?;|;I<J<}<?C@D@z@CCCEEE`HaHH $xa$gdzS $a$gd://///////00000000000000000)16181;1=1>1?1@1E1M1S1T1W1111ӲӲӲӲ~ph:h 7>*OJQJ^Jh:hr@OJQJ^Jh:h2jOJQJ^Jh:hJOJQJ^Jh:h6OJQJ^Jh:h65OJQJ^J$h:h65B*OJQJ^Jph$$h:h65B*OJQJ^JphNh:hOJQJ^Jh:h:OJQJ^J)111111111111122344ϻϫuh[N9(hzShACB*OJPJQJ]^JphhzSh 7OJQJ^JhzSh(OJQJ^Jh:h(OJQJ^Jh:hOJQJ^Jh:h 7OJQJ^Jhl~h~X>*OJQJ^Jhl~hl~>*OJQJ^Jhl~hl~5>*OJQJ^J'hl~hl~5>*B*OJQJ^Jph$'hl~hl~5>*B*OJQJ^JphNh:h 7>*OJQJ^Jh:h~X>*OJQJ^J444555556666B7C7P7f7n7t7777777777788 8 8 8ּּ֢֢֢֯֯ֈubuThzSh65OJQJ^J$hzSh65B*OJQJ^Jph$$hzSh65B*OJQJ^JphNhzShOJQJ^JhzSh$OJQJ^JhzShOOJQJ^JhzShX OJQJ^JhzShJOJQJ^JhzShCOJQJ^JhzSh 7OJQJ^JhzShT#OJQJ^JhzShAChACOJQJ^J 8 888"8;8D8N8i8888888888889%909<9=9U9994;6;9;ӹӯӢƢƢӕӢӈzm`mM$hzSh65B*OJQJ^JphNhzShOJQJ^JhzShOJQJ^JhzSh>*OJQJ^JhzShACOJQJ^JhzShOOJQJ^JhzShJOJQJ^Jh|%OJQJ^JhzShOJQJ^JhzShX OJQJ^JhzSh 7OJQJ^JhzSh6OJQJ^J$hzSh65B*OJQJ^Jph$9;;;<;=;?;u;z;{; <<I<J<[<g<|<}<<̿|n`RD7h%yjhOJQJ^JhzSh(m|>*ϴ&>*ϴk/>*ϴ>*ϴ#ϴϴJϴ>*ϴJ>*ϴϴ$65B*ϴ$65Oϴ$65B*ϴ<<<<<<<<<<U=e=u===>0>?>S>b>?̿~qgZM@hzShOJQJ^JhzShOJQJ^JhzSh&OJQJ^Jh|%OJQJ^Jhzh&OJQJ^JhYh/QOJQJ^JhYhOJQJ^JhYhOJQJ^JhYh&OJQJ^JhYhT#OJQJ^JhYhj2OJQJ^JhNh&OJQJ^Jh%yjhOJQJ^Jh%yjh&OJQJ^Jh%yjhk/OJQJ^J??:?Z?`?a?b?|??????@@A@B@C@D@Ųtj]PjC6hzShOJQJ^JhzShOJQJ^JhzShoOJQJ^JhzSh|%OJQJ^Jh|%OJQJ^J!hzSh5B*OJQJ^JphhzSh$OJQJ^JhzSh5OJQJ^J$hzSh5B*OJQJ^Jph$$hzSh55B*OJQJ^Jph$$hzShU5B*OJQJ^Jph$hzShU5OJQJ^JhzShUOJQJ^JhzShh^OJQJ^JD@z@@@@@@@AAAB~BBBBBCCCbCkCCCCCCCCCCC׽䰣{m{m{`ShYh~XOJQJ^JhNhOJQJ^Jh%yjh?>*OJQJ^Jh%yjh>*OJQJ^JhzSh#OJQJ^JhzShIOJQJ^JhzShOJQJ^JhzShOJQJ^JhzShOJQJ^JhzShT#OJQJ^JhzSh5EOJQJ^JhzShOJQJ^JhzSh?>*OJQJ^JCCC_DDDDDEEEEEEEEEEEEFŸŸūvhZL?h:hOJQJ^Jh:h>*OJQJ^Jh:hj2>*OJQJ^Jhhrhj2>*OJQJ^Jhhrh>*OJQJ^Jhhrh%OJQJ^Jhzh~XOJQJ^JhzhnOJQJ^JhzhOJQJ^JhYhOJQJ^JhYhnOJQJ^JhYh~XOJQJ^JhYhOJPJQJ]^JhYh~XOJPJQJ]^JF F$F2FWF^FFFFFFFFFFFFFFFFFGGG1G=GOGWG[GpGzGGGGGGGGGH'H`HaHƳƥ~qh:h5HuOJQJ^Jh:haaPOJQJ^Jh:hOJQJ^Jh:hOJQJ^Jh:h5OJQJ^J$h:h5B*OJQJ^Jph$$h:h5B*OJQJ^JphNh:h6OJQJ^Jh:hOJQJ^Jh:hj2OJQJ^J+aHHPIRIUIWIXIYIZI_IIIIJJLJJJK"K#K$K%KK1LѾѰ|kkZkM?h:hFpI>*OJQJ^Jh:haaPOJQJ^J!h:hB*OJQJ^Jph$!h:h 7B*OJQJ^Jph$h:hOJQJ^Jh:h 7OJQJ^Jh:hFpIOJQJ^Jh:hOJQJ^Jh:h5OJQJ^J$h:h5B*OJQJ^Jph$$h:h5B*OJQJ^JphNh:h6OJQJ^Jh:h>*OJQJ^JHI$K%KKOOOP4RSTTXX\_M`N`|`"c#c?cDdEdjdegd:gd:$a$gdzS $a$gd: $xa$gdzS1L3L6L8L9L;LLLLLMMMMMMN&N~NNNNNNNNNNOBOKOOOOڻvi[h:hFpI>*OJQJ^Jh:hFpIOJQJ^Jh:h5OJQJ^J$h:h5B*OJQJ^Jph$$h:h5B*OJQJ^JphN!h:h@LB*OJQJ^Jph!h:hFpIB*OJQJ^Jphh:hFpI5OJQJ^J$h:hFpI5B*OJQJ^Jph$$h:hFpI5B*OJQJ^JphN!OOOOOOOOOOOP%QAQQQQQQQ4RWTXTTTðâ֕{{nn{]{L!jh:h%OJQJU^J!jhzSh%OJQJU^Jh:h TOJQJ^Jh:h%OJQJ^Jh:h=OJQJ^Jh:hOJQJ^Jh:h5OJQJ^J$h:h5B*OJQJ^Jph$$h:h5B*OJQJ^JphNh:hOJQJ^Jh:h 7>*OJQJ^Jh:h>*OJQJ^JTTTTTU0U2U5U7U8U9U?UsUyUUU\VaVcVpVVWTXƳӅxkxk^kQDhYh%OJQJ^JhNh%OJQJ^Jh%yjhOJQJ^Jh%yjh%OJQJ^Jh%yjhOJQJ^JhzShOJQJ^JhzSh5OJQJ^J$hzSh5B*OJQJ^Jph$$hzSh5B*OJQJ^JphNhzShOJQJ^JhzSh%OJQJ^J!jhzSh%OJQJU^JhzSh%0JOJQJ^JTXXXXXXXXXXXX[Y]Y`YbYcYdYYYY\ٿ沟yk^QD7hhrhCOJQJ^JhhrhOJQJ^JhzhCOJQJ^Jhzh+Y|OJQJ^Jhzh+Y|5OJQJ^J$hzh+Y|5B*OJQJ^JphN$hzh+Y|5B*OJQJ^Jph$$hYh+Y|5B*OJQJ^JphNhYh+Y|OJQJ^JhYh#VOJQJ^JhYhOJQJ^JhYh&TOJQJ^JhYh%OJQJ^JhYhOJQJ^J\\\]]]]]]]]]]]]]]] ^1^2^4^?^B^L^M^Y^\^^^^ֵ󨕂tggZgggZMh:hOJQJ^Jh:hT#OJQJ^Jh:hEMoOJQJ^Jh:h5OJQJ^J$h:h5B*OJQJ^Jph$$h:h5B*OJQJ^JphNh:hOJQJ^Jh:h+Y|5OJQJ^J$h:h+Y|5B*OJQJ^Jph$$h:h+Y|5B*OJQJ^JphNhzOJQJ^Jh:h+Y|OJQJ^J^^^^^___8_=_k_}____ ` `````'`1`M`N`u`z`|`ȻȨzl^P^hzSh>*OJQJ^JhzSh>*OJQJ^JhzSh%>*OJQJ^JhzSh7]OJQJ^JhzSh7]5OJQJ^J$hzSh7]5B*OJQJ^Jph$$hzSh7]5B*OJQJ^JphNhzShIOJQJ^JhzSh!gOJQJ^JhiFOJQJ^JhqOJQJ^Jh:hOJQJ^Jh u,OJQJ^J|``````````aa&aDaEalaqaaaaaͲ~qdWdJd7$hYh5B*OJQJ^JphNhYhjOJQJ^JhYhOJQJ^JhYhOJQJ^JhNhEMoOJQJ^Jh%yjhe"OJQJ^Jh%yjhOJQJ^Jh%yjhOJQJ^Jh%yjhOJQJ^JhzShtkOJQJ^JhzSh5OJQJ^J$hzSh5B*OJQJ^Jph$$hzSh5B*OJQJ^JphNhzShOJQJ^Jaaaaa/b4brbubbc!c"c#c)c*c8c=c?c~qcUGU9Uh:h>*OJQJ^Jh:h|}>*OJQJ^Jh:h>*OJQJ^Jh:haaP>*OJQJ^Jh:hmmgOJQJ^JhhrhOJQJ^JhhrhOJQJ^JhzhjOJQJ^JhzhOJQJ^JhYhOJQJ^JhYhOJQJ^JhYh5OJQJ^J$hYh5B*OJQJ^JphN$hYh5B*OJQJ^Jph$?cccccd(d)d1dCdDdEdjdeee eɰɗ~i\NA3h:h5OJQJ^Jh:h>OJQJ^Jh:h>*OJQJ^Jh:hN2OJQJ^J(h:h~XOJQJ^JmH nH sH tH 1h:hN2B*OJQJ^JmH nH phsH tH 1h:h}B*OJQJ^JmH nH phsH tH 1h:hB*OJQJ^JmH nH phsH tH 1h:h~XB*OJQJ^JmH nH phsH tH !h:hB*OJQJ^Jphh:hOJQJ^Jeeuee`ffffffffffff,g-g/g B#&d P ^gd&~ $ a$gd&~ $dxa$gd:$dx`a$gd: $dxa$gd: $da$gd: euexe|eeeeeeeeee_f`fffffffffffffʽʽ形{{{{aJ-hY6B*OJQJ^JmHnHphtH u3hhY6B*OJQJ^JmHnHphtH uh <jh <UhzShROJQJ^JhzSh|}5OJQJ^JhzShmmg5OJQJ^JhzShN2OJQJ^JhzShOJQJ^JhzShT#OJQJ^Jh:hN25OJQJ^Jh:h5OJQJ^Jh%yjhOJQJ^Jff-g.g/gHgOgTgYg_g`gagbgogqgsg}gggggggggggggggöööçÝyjyj]jyjyj]jyh u,CJmHnHsHujh47hYCJUsHh47hYCJsHhWB*CJphhWhWB*CJH*phhB*CJphh47hY6B*CJphhJhYB*CJphhYB*CJphh~!hYsHjhYUmHnHuhY-hY5B*OJQJ^JmHnHphtH u/gggggggUhVhXhiii(i)iiii $ a$gdEQ B#&d P ^gd&~ $ a$gdQ $ a$gd&~gd&~ B#^gd&~ggggg-h1h8hShThUhVhWhXhqhhhhhhhhhhη|o|o|`|Q|Fh47hYCJsHhrhYB*CJH*phh47hY6B*CJphhJhYB*CJphhYB*CJphh~!hYsHjhYUmHnHu h{&HhYhYh" hYsH hYsH-hY5B*OJQJ^JmHnHphtH u-hY6B*OJQJ^JmHnHphtH u3hhY6B*OJQJ^JmHnHphtH uhhhhhhhhhhiiii%i&i(iiiiiiiiiiiiijԺԺ}vh_UhYB*CJphh~!hYsHjhYUmHnHu h{&HhYh" hYsH hYsH-hY5B*OJQJ^JmHnHphtH u-hY6B*OJQJ^JmHnHphtH u3hhY6B*OJQJ^JmHnHphtH uhYhYCJmHnHsHuh47hYCJsHjh47hYCJUsHiiiiiijjjjj $dxa$gd: B#^gd' B#&d P ^gd' $ a$gdQ $ a$gdy j!j'j(j)j*j9j;jHjNjOjpjqjrjsjwjxjjjjjjjjj述hzShROJQJ^Jh <hYhYCJmHnHsHujh47hYCJUsHh47hYCJsHhrhYB*CJH*phh47hY6B*CJphhYB*CJphhJhYB*CJph21h:po/ =!"#5$5%q 21h:p9/ =!"#5$5% F>FDދ^U2GJFIFC     C  I" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?((((((((((((((((((((h/O_>0EhI *.Ehb 88Š3/loRڗ-gK7nFO\*yK<ǘv-G|%CsƲ&vycěbӴvh?JocFHpq(!q'T< >j|MMXƒAqhچp(io,"1㌫ҔQ_9x-Tx{¿7xVOXZH]O;xEfy$ (/ٻU>o O{aEٷ*:U$+kVm??~-LJķxItIb+3œq.CWM_<5 7ŖVrj~-VZ[I1[r碻h+s~%rmcb1gu ~G7/텩-&*zhb7MyBqu]W5g=/>I<7cg4nma*+qXhžt/Eqquems{u=UYJ#AHHfb+cK9e8yc]@̯ k/w??Gۮ;schг$^`R$e.A b:P_#YKR5ڂGN쏭,V\_20dB23 %Q@Q@Q@Q@Q@Q@Q@`z+5orWni?l/5ē467f'j"Tg@ Ҡ 772͸I7qiWG G0\y?U^ ?/n"k+?j 7cn"k+j 7cn"k+j.<ߎ_=~ ?3ߨ 7.<ߎ^=~ ?3 7`~:}ڨ8_0/O~.<ߎ^_`~:}ڨ8_0/O~.<ߎ_?j[Zm?=`~:{کj[Zm?=`~:}ڨ 7cn"k+j.<ߎ_=~ ?3ߨ 7.<ߎ^=~ ?3 7.<ߎ^=~ ?3 7`~:}ڨ8_0/O~.<ߎ_?j[Zm?=`~:}ڨ 7cn"k+?j 7cn"k+?j 7cn"k+?j 7cn"k񎇣x:Gi5"H! nVRTstT7߰|YM)96opx#G S7/f9?iwƿ+_A|4ZnqYd&Wt/nUB(E c'T_< گ|CuB."VlᔲGMK^-ߦ\[E"|.w+`k~g31Cj{:pթ;G>#%^׵u>_~(ŵ>0<-oZ,զV($l_?Qw?~!5& $2[E]_V@~[-+qku oq ,l2E W>PNѿtiq%jQN\ҞΪrҊVg|3+:YjPz.^k&WvrF$WĿ u՟~/ƾ*5m7q1Z1y$7DWJhS>:{ګ刟"2ӿ0c#7'tڿ-׼,?V/ج(⶷Q,33|ƾ<.+/VRT)$l;+}|5~SxV?jߌZWmn?ty6ۣˉ<@8.<ώ^E ,kI*Y,clVU㱷*㼚>5U<9(_&}Ex_rCڽ4`έ"9p[9)emp÷^}z:uYgeef>ki4QEbzE @5/qnN!e/ Ry^T y$NJ;$AWnՄUT冉j.(⌷p &NURohu=:~MqkFc;abn@8g(uisjvcBi]a=ƚQ/mC*~K7\v61Q^7NU}!?D@~ Z]ƥnyIc 3 ޣzL|I/ KCouKY64RB?|M0<3>'ʗGVR ]6ᵞE% guHmjd"W>QVw <ƚPjkuqn~M]gתsޖQ?nD$dM-7D"xpl$Cpp}EMw^Gp|QqRMZP]$iEW9f3_xw2&>"!rvǑcd_B~ӿZu)מ:mYjZ&dvYX2 9tNa/&{ΛSբ%jG_F~_JكEҭui<1oF8\VTa'{Ec1?/T::؊ѧh3r3BOö7B?I5ޜq]F;|Ϩd*a]ῇ8K$|+ku|Wh;PؤvU76څ VHPz3!ɡK/[l| ?76ֺ:[ QЅ+0q>`lBt yQVKx(֗Es xbSKH֥RUi)=:w _>S4' /vڧJKuĿͪBVп* bVkc(=G}SGUrz\RNZg2Zvil7>߳֩?엞<-II|&iCFA`E|u_oO''{#h-Em3C li'=Td4S&gGkx5GvhIrmb;ss& #W,~70*X (Ԗۻ+y]ÌW:X:MB|iרt.6Y۫~~6u.7C{ U5#Lӧ?]idq]F|yMb1QX6Y_<3!Ia+<} _vj1^<;f&M8<N_^u4HGI >74sDR9UhۆM|-|Yf%6^i[~X) k0* KUO"YEA|[N?e2K>&x%$S*O80\R@f 0Gᗕӡk8TlM8Rzs$~EퟔK1 ז~_h~? {'?_ {y2}o8ϨǼ_moߍsrbq(($SԚ}CӁ`A&_.dn+kԪD,l*Cd* ˏʽs|l?O}SZ-DHK"o{o Wԉ| U<cqW`^w9=7X^*QJ)QQRnj e /QFui1cnVOS*J&?ZƗ_ym1]$D, bjڇ$>xw\jz[gҘn"[r!DJ~&Ú> xJk/xRVܪ2Z%o$3(gF۲9CRw^? چeg.Y/jߑj;Wٯ厱Y?jM43v c Fdbid.Ę'G>:=*?xrxEFL#LZ6uepجk~ kv6 t=,#XۖZ\廙gh x%Zng7Y!{XDo!.;?>h~M6Z-B9ubC"@7VFeY>i O!?o6w\Go}}2I,2ɞ*nfR'ˊ q'ŀ3=4?s/Y{_D8{FKџ}&ɮ|:'KX{'/ػ}X?gït%2"ON~S,I ??mi&釥yi&釥F/tpx/OH#?t}~W[O_M5^C+gG$q_/"QA8 `YehO h6kD\1aLl3~mG8Z.Wh!RNjьwoDMM=]t 7^ mcۼPĠ݈UUĀɯ?h._iZ@Bա2& ƫb) w.p,Ãʯlh]񻮏%tm@a?- @!pҾ1J6_-Ke?E87g>X)NMj~G?inU]oxʢinco CC䚏 K{1;iEGl 7sWϳ/c rj/pUSX uѯ~2qZP𞞩 >D1>{8u~蚕̢Kg,"+Jރ̌{JjqZO~w1|8W+dף?e(wd[?k>֣#8'E׸Wkz׆_xsV h2H22`AdWg @jO/B1߉6]mUrL !AeaWQGT JQ٭8:C9WYZԦ4]jI9/к)؟!EP??Jk#ſe}p+#Oї`Y?.ÿj((( K'tۃCڄ'KkRB.%2"Ed.??oجo n"nnGV_d4 LnE6Bːp9K5?(ss,ϑW1` $o'ܥRi_~]Fx_ĈѠhf0Vʽ+9I.~y+eQE#3^I7?x#Sh|Sx-fZ%c%])xo'{ "^Y5`i3Lʩ~ Z?/S tcP~RdAHtg/ac)OG#EqbxR)Q§]U^s{-Q^1PFx4Q@$Le 73 ,|]8Pɒ ޮmW+vߴKO~ _^" GDpA; ctI@Ak?/=!Ծ ־,Z\m!Xg%o2AُA{*hu_?%Ω l>qCc׊U«mn՟QMCNh Ma/xoP_י4D̯ ʶU <ݞ57"~zvOu_|Eo专 i 60O1<-I~6/5=CVK5bD⅊ z&WMo"-:AH8v QGjClʷ vgZZny*(񐡆֊(oŸuZ,makX-*%UHIظH ƅR;*(c "6bq)VIE6۴b좒Il N__xjKm{R&K+A=¹yUG;*Wk'z. $~cyrNg 2w@v/g !4 Uaiర o>kŜEͱMV#bEy +##g{5> ӻ0*8Q$G@+6⠎ʊ2{἟'ƔT,m)ڳ]'ҵ*Ǽ_mߍq~4W(??zPϧΊ橪;Y'ۻܲԴ=;;?#?nֱVv.gԱF<* $U9ZM->h5nOk'LQ㨯o;RYw˸?/b%yܢz+1~ܗ^5(Fo;epc .cv5רoz]5Dž߲*;1YP:yq9"4qk/VEW5IV[pw폪_$<_f6KUL%ݷqRDžSWW/6?:|Lo.; #v&e$qdkkE%pD%O#~0'gwQu&# pZXOtX8'eN\'^pMKi/_# 곳5]f M[xgo<%@Yѕ,߁+(\qEs3yQᧁ~xJavN٭lQRIgbIfv%f$)?\WW)B_ua~>k?3=4?s/Y{_D8{FKџ&|v~ɟkI:$?.;&ĝ/IcHSbyߥ/ /BxG/ɪ|=FDza^gɩ=FDzaQz'1$ "~H5]/s_#?t}~W IWKHV7Ú;^x=q$B[;K0>ƹ1+3oݴR8gֵѣǿg֕x)$ֱ2[]3s~ƃRHwi~,`G«G8UQ0\ڿ$o:_.f-j^{Y K0"sWu~㥘etⵟ>.p Vu:k&^Qm (sQ|5{}i2~GO,۟Qb5Q^IxQE+/%Ư֚RVl#XB|a]'Լ]],:Uח7H k#/{ښ嵖|=O+K^q}yWM( !eG(6lWG1xâoHn.E9$ )#$b:E]y|%k~>+-V`} \}cݻ=;ͥn?iB_i5C L&~-&LmcqDUp?d}>+6i( %LkV2N?n c nJqOM^O&QE}0QEWĿXoi/h Ζ9[7\f9jg Qk*\>= H~8]]oc/;?Gω)v|Jm5?~6/ oĿ~mmǮ趷Wɳ=ݏºҾqUſ4/4ۦuo4.=@1ھ<G#|s0Z'⹗_]-9CϾ2dé]4вw`cߧAL ~ n*ieOlQnO ZK~ҟo~8XMn x˹nΒkp?1T$չ_x/0𗇱 bhOuX'(6GQEQ@Q@~do~gjĽ5$V@Py Ϯ+ڿ=?gsOdXTyp*;lьw^S*$~.ļ+K5UJWJp7?Bi߲-F_hpOy;-s?dנ潚u#V]IF~a2eL-xΜdQm4 ( ( (q~\~4W={Uq?)^;GX?KUWq\[U/ZoowzfŹDMW<cqW`_;A? h^=hŮA1Uf$gO ͱYNHq??(i~w▕,z֕ İ?MK JN2?mY#LfgXaj9BrveomQ_<~1Pq[G'_ԯ5iO|dgdGտ౿9/F^?u26Djvq_m 1<-|񧋿fO:!lj-%@1\qBFʼn%m&ϛ[O~ӕnӎ\>s ?(蕯L=+>~ҿM?F_ 8m,5K'Ihnw $c)9a?[otՖG4oFQ<t}.T`x Eg=iMlgnKZNvNWGG[O_M5_?Mo=K7u{M͟}DaEWQ@Q@Q@qOIoi~"BV)?&&0񅍏yu/ODF7i~GŜsh}^^aUM{I_ErIx𚕮mquAD_C\ vރSEh t~pb]HiRT/)n&(?~GOWHoHic[U./ %q`q6~_<@'e͉xQY?7?7 Zo5˱WְξjPNѓ\~8Oſ 飏׭МW?g߃,Ȥe-[Ȗ0˝s78!b8zkbeN <k;[2r~QDT| ?'ֶhlwі̬<+{ׇ~«GkhR~1%\ ,׀į|Mo._yuʓERN_(%u%[A_`-0ҟ:KE= \kg?{(7(?)vR3}T?GV-GݰH>1'ϰϰG8{.Ǭ6鶳ݚ35;4ܜkϕ9&>).]9BݵnW|#ܳ>OX|CWåzҶ6?鱫<;FOX{H5g$s>Go {/,~ѣK5IH;]N[VU#_OL_S_OR}?z[ķ@%3Iq2ۈU!fO23_:C?nφ˥GIFo EO&`9xN{|gRPaOd{⌣w(ʍX4{ەru~RPs 'xgOmf`|\y`_~~]/~>|E܁O P\pH ]s4cӊf($U7|?8>qQ*JST٩+˼efu(^EP\_Ci>"岼PH!dFãceR9PFS(qqz3l>"+QԢ֍4}NCĿM'?O7AՌ%܁lN`H[K ۷bC ZVOpGq;~ Ig~>cF2GrM/Pjld4?Eil¼ep2%K'%2'7'-̻[߇O 󼏕f7ᴋO{]Er~6|*oyGQMwCyr/ 2º]U}$eR}O|F׃$Mnz0*B(\Ǽ_moߍsrq~\~4W(??zPjlWNe8" T_Ueqo^~#ʟ×?"g:NV>.a5,mude2A _P57xM/JҾէʒhs9XԔ8[ou (\>_o'&W-!)1>[-ٲ'"³|3ڗ䰭(y*kī?~5+xZ&L{$yw}l?#;o3Ms:_^w# ~>(47/Yحj.䱫ʋ"6;_Ӹ~kk4˸P?u7_Xt!!?/Ɵw6mJg.9 M 56v*zez/_ݗ~_/J}#÷O^IQEQER?ݥqjo fbo;Gϔ7aˌ~0-|SD$da$Q_wg1~_N^@Ҋ+?P8~>Ɵi!me6C H_OY96>5jaw7P[9 5Me^v;+Ei-~ 7 U(u_,~}_[S2 <|]kpkYodn˨eeff0@m/hf^c`FC8 }%%ďg{a :[,eBم;8OD:[~ʿ? un2XDσukռydtq̦|>k϶<+F/)6> x&Q-e,4':% KAm~խ ?PeP":Aȫ].~'(2qjQ@ߍ~ χ!mm{ KC :2 Fy5QS(F\dobpxqwڒkfMwGO$gMǗ?n#P1%vD ܟB~I C+]bki-Z}v\/,\er\y -~2 m eB]?ĖV6EYQs6a~0TS_'S-/WX5?au8tQ.QkEuRWvVאGuip"HrT?;ӿo㝿ac~6 ^Y'M:&mk8Gk5&xHX[qgyg2:IԐA 9e<|㤢OO|opF74F^XӃ/vq~\~4W={Uq?)^;GX?KUGtm$Tw* ˏʽչIr#~N-{N-^RK1xH\bÛq+dcF+E~*~qKҸto;Ԃn~7f\iRMӔRqqNn(لa+[ |C㎗kOk4GtۉX؞ &r}k U쥮KgnPd+Gi-z>+깄$z?G,p0WM{Xw憭/7h6vGy{2MXuC?"&)C:3UOUQzT~_ [_g>eᾩ>gDZn<vMQE}WGNwEK/k4?s/Y{^z33Ms:_^^{&ɮ|:'KXЫg;$SPzQAX#?t}~W[O_M5_G IWKHQE|QEQE po.lHK,Q@bO޿ ?P)lߌOڵ+ ښ+&܈6J32ȵ dc`FkZޟ1̬ <ܓ*̐1_^x7_z.~':U8VqNfqdII;Atoy+#p:W񿍤~%h'@չy}/' NW$2`/؟߷K_D7V;kЮﺬA_>2̴܏φoΧ:ԋgÒ!X,ij$k^&Ʊ_/ў;*.gӰ?i>騴H(鷡ٲϷҾ=o?k#ſez?(Ë?d($<_S{5Lm_HQhHq1,DeG?3g y?U5+m[lUҖ.m_h_y&5+/?b)nO*i)+-˖+d.Ij3OL;>~_16gҕZ37+G߹)|+lj~|HР1iWo1K HGU&5G|Li4Gd#O2}ޭxP;g6$GSx Oj Ob!/Gfʲ,V5{:sC?W/>vl$mmHWC8{_~ǚdZާx$R 4qcPZ1/;}~xg[9u +?e?YpQEtQEg^7rj_ |L*zזm$QV씌:i)JExf3dم,vniIJ2[Z=Ώ!1}6_xu\\MCto s7ENdJъt.qaGh ɤ>ǶL'<^>h°շɳ٤xOɋ<#3 ̨ƼkK˝s_ (0((n_MKoVº_NU8'"F8eWgOx%WKEEEi o&Ȑ1+1+3(DDߥ~Y~֚w2[ZƱJ}B9" 5ɤ\i|>N{m(ᦪW{xspgy{)pi(Uau.]j?S/J+OF\Ǽ_moߍsrq~\~4W(??zPX e_THٗ>½Ź~keվ _VI%GF"QSz,LWO/*-㯋FxMlYX5:"t9 ZQ7ʫ4y{;r--{EW~ZBG$lFːF#5-JJ?rI.FϥN4=+';-|5Mo#PmUvY,Y3 8OO)Wsrj$?ڦĉmª[3Ba\f8Žex` qmsڊ2=(?} "Ze~WGNwEK/k/F~3}&ɮ|:'KXЫd5χ_$KzyX;תB J(=+?$zok_[_?;#Š(?~ ( 2S_X*|(Qf0Tѵ梊+?O  b?tx/q$/X`n,XrJzU/ h9[^k;m/ Q{eX]8Z]o!82mCt8NTӹ-vg+?$ >'|~ -۴;|[ș8=|CnffD=|g,¯R^ugcY>%7B^q俻*mYEW~QEƚDS5~ߓmjG~m%C (^Y`I$}f?ZC$h_Xn@hkr-ݐsLU:jj7_~c}zøwuHxҋS?Eg#ӾxEֺoajG Kj:vkʔ?JJ QMZ1I%%dMJ#"QEQEOc}G1Ƿd}sGq hPL،e}Z闎OYGLq_/fʋntqLjo|15JuZSɥQEq^QEQE?aouI fFdUǷ9w_?]o_ {5H<+ɬ2~0zc5yؼ ||.&EJQGxbDP/-{.?Oˏ6oƏ|9JGy??ʿ.??+q?~ixX=PJ.?*L%ᾕ-ǧh4~+~qKҸt|#:4Փ[s'6.:tJ-{99$k[g(3p(m_fx26&ET4j4YM|u-sྣ{v"LI$?o^f'W 3Gbo۾m{ÖGe-gH>1#cklݮh6?Z2~+xa?cV+ϗfSETu3:-Eug}n08d7PGPAJ_;2t¿4?s/Y{_D8{FKџ&|v~ɟkI:*3Ms:_^^V+~?N'ҊJ&k$zo>&|W~H"_E0k:|B]P-x9TwVrn][[vw@rhZ஧ڟ@ |[->񇴴/?{+pR?tOҼqᛓ6iXTR u$Ak A|ˤ#DD%Tbv3HoxN'^&ƖY ˷;7%kةٕFj z2j};*ժ%8 Q^9_kP|D|I^xnA2.yT@S69 |(*5<+PfYb;<󐍒dʟO_/~?޻?KU,WS(>_C1|zJkQwe{_^۟>Se9x%*(Wu?P_ƥ?j#?$mT?*6K B?2}/Kwc[ _RW6#JӋu~c2>4"̈́GBMF_U(;I4ݛ:Fbҟ~/6yf֡FabxW_>)/wj /$#S^\|}$0x|+սfYphQP|&F0mweݣK EOjĚ:E|g33He)vӮgtNYGb1X*:w4d;þ#a|:qt.mJ2MkE% + |Q{#&c;'U9*9M?w}S; ա{_/ٷ8{41\T9MIy4~ep8p)N%K?&Cz&| >6Aiv5Ck w;qF#h+??\AvZGFEj )4g'| Uc¿ l.?mo<wIw:%!Q2(]Ӕ(|ʶTa`o/S'+=/9=^gpxTVqĉVTN2Ό]9OdZ]!e( %S., eonaO8"i#c @ | k᷇`Ҵ=-t|8ԒY؜;ř$]^e8ѽ}l?qV̔=-!J!J Mvәh?bOW:7e {R-qqeT O1b&CϙTCyK00>j_,>u%G4˹;$\ (aOjvv- 8'4ܫ?2&Tս? ?x<):ꖑ'VR=.ԯ- ƒxOŞo|!l$c;9$`\21 g+/NFo Ԅe4JsFcݍ%-ʎ@XzUwUoiٮ><)29?v_=a^sӵHʜRI_K}AE`QioN,>!sh_ Zwyc8|F^?b/E{oV>4՚Z/nP2{c @A*p[S5O q}X\ RKфt]۲]OTi~5ύ=)>5;ɵw;u mF#!P(WO2\f .&~USU? [|n$wߵ.wNSl%|*Q ? x'<9oz-Z};bGrij1<,K1$| pҨRWpqo_?Y9K_,"Zeo2^zwWSҏ?d5χ_$Kzy&ĝ/IcB+?WpOOHAAE`{[O_M5_?Mo=K7u}C+g?G$q_/"hfV?eI gYMedaȔ1U~|~7Jnk_;ZM_nac.=O+yqU|FgO,,c8.NVNKtyAWG }] s1i&xU_6v?U?n>_6v?U/ɿ,X_Z7/x(ۻ G(ۻ OoD?,X|Yg㦘_n$BVxHd"H@5Y)/wTNĭ F?D~}vl?D~}vlR6Ivr72l8zI3UN_HSAPյkQQգHm& > |*1=njDbēHr}D~}vl?D~}vlUVīUħo$=])K77@K}k?D~}vl?D~}vl?>bUFwᳱwᳱ?1V#-y֪jFi>[YBZB$ha pA"/GGkGGkZO^&JfQk+_??wu>m7nZ [w[Xr~+Lki^ #gcQ #gcWSZ暧I/(,uGNt%esWm.lr??Wk[0׿lNF0mcqLAk+KM>-,c@TP0x/(ۻ G(ۻ ]|-+I~#qb| %I]x>M\7PkTc nKxDzDˆTˆU͈ʰ8֔%|H.X\e ='F7Kw<߱r>+L5OKIXmyUKg$W[ #gcQ #gcW-.hϞ $8IŌ 8=SϖmwOsޭm5 qE:R_ZQw];*Qw];*?ɿ?<̯y֍^ #gcQ #gcQZ?7"/1V#-y唌Y^_  xWMѷ17l8zd׊ˆTˆTFɿ٤bM,ܾ(ZYʫWˆU۩linVQ_V##>Wi2[YV#-y({iI./K`:Hw4!FX@+#e+ॎdlilj#Ԛf,p%>!0zqkS4p9B D? (($dw=rѹ}k?D~}vl?D~}vlOG&O,X_Z7/x(ۻ G(ۻ OoD?,X_ZBCp+D~}vlQ'?n_6v?U/ɿXb?~^ fnE6*fi|,81vwo~??>lu2 O1p9cWP' `ƾ~ߴ| -1|Tkh3t!h#𭾚֐\:#I&+Ă/|1ڦ? [FR=mᤕdI9L6hQ;+W^޶~:m પxRtn߽ƴvt}kK sNK_,D~}vl M?> >,-Q+jqqi+sst."Tჶ~; "f E$z5gTSZOrﷹVr駩;&0]u:_^}k훫|f?6I&U'հ==;5ײ/|$Ǵ+_6?U+kᱳ㵻_?7"4¥°/=ʊ(SB(((((((((((((((((((_^/<3?~^ GoSyq*V2VrǸQ(Og^#ox_YAjV'megl(W'?+b2l|u'/?o k?𞢷:{˭.pV(,̀,& LizOXԴhtxjhmS+|ʬaH_.L#1thF~Q]xxtz~ k.o#VyH_s> 2>"Z3CаuVFrQp;VR߫NW RNPB+((9@_X)|"{C5SISȐLx0ǑLxL_~˟mǷ;1*jY2Iix}n-汌;U]QV2B3G|xk u+ֱXLj-5m:ΜiWd*$bk7LuwŽƾ l񟍼;:K#/Mxao1P#O7gke~#]Z0uaf✢)Zw?]f6o'G>-c+h,aЪt?\گn~?(ịwK/⌑% f["vz%zxmf[\`Ĩt }@kɿd.IU?j7ßjG&E'Sl6u2OC,5*P=6'3 luէtfui M[XOI|=FkA-:Qo r,DI!$&Ҩ`9a=_?~K_z/ohRkWY\}cM]mU_5MewNJ5h$%K _UY|$Ij>ִڷv쏱3ٽϳPγóQ<7k="MUen!'$vA,51WzKG:/YBK+oi"MX!p>ͨ]b#4P(fYk_ůi.}}Y2["@vmZJvy~[T,RwjQWWI^+QEsQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEW B_?jO? ~5xJ-[IU!5‚xdR93 OsE|m~1K'U-jj͎ PqЎw >xOZ[[PO$坙i,K1]5Y )QEQEῶáPִ4,wvNLMYe;e,M| ]5?~ 7 I&B<)FppG\*9(sὧx66:mU !n[%1bK~|񷍮:I;GKMoŷRx.\n *]*u%AߴO]f `Dg2XDZi6&?Uh]x7Ǒxw㗀>e{>{[[I3;QW|]x֋ki: siwm x#aGQCMw4h V|uqoz=Sm7no/-ǑFC <2<| 6 sj+'< 6?z֭B3FdF=k ~~*_&m^%ƱbЋ|Vm?kcnxc 39QHaE俵د׼Ys+vZ=7L)2 *f {+5Cvծ] ")iks; %g__]xCx{㏀K*M}Zm=8崘2$td#ŠxbZouM'Tnm.l2H+FGDU$(h_ #7ELHylY8݀T2cCAEQ^Kaپxy%c7z$Y J+ W~՚ ,tHdeGVT;%13U3Wo7]Zliϥ!8 ,as0vVO2?S(k|xsºZ +АpU AԔQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE~CB_*o^ѵggRӬeiu,F *+~=DӬ+NCkgi +R!ƃ⧏J;|jg猼GrVlɓ$IUG +S/hnt`kLx 7:\oIlm^ndX|=Ǻ Mh&>.jp_xķå2:uR4,cݑI70hP8-} xL!7Zj* QԱdI wԚ7fw&T~ia* $vd>e~fvd/V뫪Geip^=-?_UO}:SU⌇k+xռa/#`:RH74?,x77ޓhk߰+߁? qFװނyIHϺQEgP'W-6*rDrB#=? N x̒y eFGmgfd^0sY`b]hPdEcHyf?>Ҽ(' ;3:mz623_d}_[fvDŽ6x4DJ apK1?5_|#\jZZkۏ1O$62|:!rGpGo]R%vAWa\/ _Y]z v=(+"S?௺\?<=Onu} ,x`&b9P+޿$?e?Xh^*x#7wT7SĜcLN"L xCJ-4}N4V֖p0UP[K[ǯZh@'0vLLp: iK}zMxW+mhVq&X zGr¤7㦯>㏅̒Ӯ);ʳx?W4rkL-)?*5-O.$O_B8X&P6d ?Z|-+cNխ 6WpԤB+ |¥u}kKg݃{tomIkᯃí@GCmqE?{!-ٷET~?#Jaڇt{k%>˶1d ]Uk aUU@ 1_I/[_>OKJ--ݴ` q4nO@+[߰\g}^6lu5 ƥբpr`29 ?|IGNy.W'1] "$͎x 4gs7KaHt]kR!GRK`tUf<)߅77ß^3],]̲=Tgv4}GQRQ|xwxg/y8 Di%V??΋~Ϛ>oc6mֿ~SWL2ǟ.2J*0b~X~ |{XKO^\A>Z܈'>\ȣҾ?i#tPy-A[+|7M=U$ԯ,m%9 rG"I AAȟ?L)iioeO)2r+#9H  _NfMJ)"$w"?\(#-j)/VxCsiAXߢf #_:#{lk|/닩 ϲj9Sd #|='G4>!B(U!JMW766>ǽ<9RAl"m"9IpAw/ '-cž&OѴ[vy'fªI T~r k? h_5YOV<.mn XPkWg}WkvH y}t.]Tb!ϧԪnLv (((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((K M ComkKcuބ7nGU܎27\W? ?ࡿO A3ė:f]YPpeu2m+6}zp' Gn29'eS*Ӎ4֗o?1~$\C Sޣ+&. K*p dp+B<9}[$D82ŜJ(/ \;F4ە?0H<;Š}*mMMtW?mh4N kMgfE"0X{EO_d)).hQE#Hf&e)$nԌA;Wo5x_rB5,XHGG};y ȎXO?$00=~QM; :wd|Tb|<'"Xi֗&D|6k'H>%]!Yi1y[cV9_0?(qѪ+JO3G 8usxXLF#J_T]QEyg_+J?zW͠jeݾ Ld  IW+6 O?)mri.,?hC;Au%t]QV#_Tm_F%x{ [0,ra ~^k/gMgE^# xZx.0l~ERPè%{dԱ>Jo- !nF9yovbI=|c 35ZQu{ge'ԫ)kJK|w ^< 7%W'(1<3}~_lxCK'&Jm UX_JHOIs<sWi^ zq|?˲Tӎ)6x}OCl$|`&_[>%峵<\g|#s5F~$0+nX(~:< oOLoAHZ'!n6>1qʔS\mwQEx'ďZ7 :[ݴ=8 AE~Zij|k|x[Mx.;{{tlLCr$-kR`kZ>~m[wJK&oSࡐSN iĉԡ.5B1 pH́Œ_EO ׭5}]ya|χI[2*9&*3d^EW}WYٯ?e KĚOiz|Is RFߌєG9 i&CoqjOKfO1y&3v:U%`vzhSS_B~˚"}Si*[ #Kc dzQi3ƚka6~|+hv'6gNwg__SRoEt?rxRT')F.IJm-5<|MwǥiIg;|ҷHrz@s$((((((((((((((((((((cE?S1?truZ>~!Ж?1G_ xrj?QO9_×|OC]?KGr//HKoQ O7i+ruZ?˾'AIh[?BXiS1??F?|[]?KG9w:? -Q??K#/j?QO9G5?(˾'AIh.]%9o? c$} O7i(cE?o9w:? -$}G-\B,b䏴F? xr-.]%t럈_% _5?(oWſ$×|OCs >cE?S1?truZ>~!Ж?1G_ xrj?QO9_×|OC]?KGr//HKoQ O7i+ruZ?˾'AIh[?BXiS1??F?|[]?KG9w:? -Q??K#/j?QO9G5?(˾'AIh.]%9o? c$} O7i(cE?o9w:? -$}G-\B,b䏴F? xr-.]%t럈_% _5?(oWſ$×|OCs >cE?S1?truZ>~!Ж?1G_ xrj?QO9_×|OC]?KGr//HKoQ O7i+ruZ?˾'AIh[?BXiS1??F?|[]?KG9w:? -Q??K#/j?QO9G5?(˾'AIh.]%9o? c$} O7i(cE?o9w:? -$}G-\B,b䏴F? xr-.]%t럈_% _5?(oWſ$×|OCs >cE?S1?truZ>~!Ж?1G_ xrj?QO9_×|OC]?KGr//HKoQ O7i+ruZ?˾'AIh[?BXiS1??F?|[]?KG9w:? -Q??K#/j?QO9G5?(˾'AIh.]%9o? c$} O7i(cE?o9w:? -$}G-\B,b䏴F? xr-.]%t럈_% _5?(oWſ$×|OCs >cE?S1?truZ>~!Ж?1G_ xrj?QO9_×|OC]?KGr//HKoQ O7i+ruZ?˾'AIh[?BXiS1??F?|[]?KG9w:? -Q??K#/j?QO9G5?(˾'AIh.]%9o? c$} O7i(cE?o9w:? -$}G-\B,b䏴F? xr-.]%t럈_% _5?(oWſ$×|OCs >cE?S1?truZ>~!Ж?1G_ xrj?QO9_×|OC]?KGr//HKoQ O7i+ruZ?˾'AIh[?BXiS1??F?|[]?KG9w:? -Q??K#/j?QO9G5?(˾'AIh.]%9o? c$} O7i(cE?o9w:? -$}G-\B,b䏴F? xr-.]%t럈_% _5?(oWſ$×|OCs >cE?S1?truZ>~!Ж?1G_ xrj?QO9_×|OC]?KGr//HKoQ O7i+ruZ?˾'AIh[?BXiS1??F?|[]?KG9w:? -Q??K#/j?QO9G5?(˾'AIh.]%9o? c$} O7i(cE?o9w:? -$}G-\B,b䏴F? xr-.]%t럈_% _5?(oWſ$×|OCs >cE?S1?truZ>~!Ж?1E/+ JÞ!YMBYnpq5{w_.:Ŏu3m';wʼv-8aR30q#Q54/{{K]wV0ς_Í'DŽmn x&Ehe-RH`@_  ~ABx 5aAe FHI:D{ao`18dX5y/*n} O7i)KoW$×|OC}G-//H'?i6sar$ĈЕ%8z{U-/5?ZRXݙYk 80R9s-!FS*q=N&tOwŞ5f=OSIL]VF3mcE?#<|?ō;qֺ5Ψ$FH_aBB{w?˾'AIk1fWmnwX<."Γn)nZ޻iS1??F?|[]?KG9w:? -q}G-?K#/j?QO9G5?(˾'AIh.]%9o? c$yMEǮ^jm~ϗ?hsmozڕΝF1nmg˾'AIkp9^WʭN~qxdrVrKv[_3/j?QO9G5?(˾'AIh.]%+9o?~!Ж?1G_ xrj?QO9_×|OC]?KGr//H|IğúCmLI_Et1 1F v5I|;пgoY^vw~ื[X$[hՑԸ*<+5'ZFZrm +m^ #/?ANc- 6? q8l҄*vχqfcxJ|rY+k}oSj?QO9G5?(˾'AIh.]%+9o?~!Ж?1G_ xrj?QO9_×|OC]?KGr//HO9ֿ4i iڳ;|OjK ? Zt+)|9< qGknmX g !XWQO#|7EcȖ\-E,@dي{?SfӟQi#gVU(2pxlpc ݶ?3!Gb1r^^}o_j?QO9G5?(˾'AIh.]%+9o?~!Ж?1G_ xrj?QO9_×|OC]?KGr//H)?Y/x[ZmJŵCw8Co'|S}M/S+A"9.H'1_7dӡB\+97;U2Ng{O5 ~ 5;M:RWeWkr=ɯ_j?QO9__➉kkEO*Hjt3>XENWngCq>-O#,Dgʴt>cE?S1?truZ񾣖 c$} O7i+k7fXi;mދsմ2W$|XOx?=wķ,ѮЬW"* ' \EƵCj`+¾OIu#S ; |Et=.ԯi20݌E} O7i+D/Q-bH:p! ^]?K]ycE?S1?truZ>~!Ж?1G_ xrj?QO9_×|OC]?KGr//HKoQ O7i+ruZ?˾'AIh[?BXiS1??F?|[]?KG9w:? -Q??K#/j?QO9G5?(˾'AIh.]%9o? c$} O7i(cE?o9w:? -$}G-\B,b䏴F? xr-.]%t럈_% _5?(oWſ$×|OCs >cE?S1?truZ>~!Ж?1G_ xrj?QO9_×|OC]?KGr//HKoQ O7i+ruZ?˾'AIh[?BXiS1??F?|[]?KG9w:? -Q??K#/j?QO9Ng<BjKW$\1a@g-%8h[?BXqȳFHeaA"ateAwS_&`}hq8ۥl~BU%J2Y4{>mݢ)Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@jg^5}{~mC5u+).D8ݰg|g %xE~ԂA7gW9~.c'Nn#?_B|`'Axد֒<IhQUaA/B+ѾX81&=%=Ͳѥ,;Owgֱ~~$'n漥׬߲iɡ^RB5k__V?4+ ZF-k8o#BQg~_w-_ ‹~WLJ>$!EW^ieɩ|B 5u柶W/[U/ȣ^"?C?3@[/j/_ZrAEW~SO2ۏWWM?|mn?_m]y?/^:k0܏z?e9߇?4iWpu~?sh?*."pґIEW'vQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEU]kV@7,y*2B8A_9ގkQnݏ7\*qe'+ۚI^W???౿Ə{׿X[fb"7 }/ O=k,o57o/A5gW???౿Ə{׿XGf/}?#pKQ_4??1>Z} _[Z}}:m`Bw#*4X7X ^3qVK|L])ѩڊ(s ( ( ( ( ( ( ( ( ( +A?떚Z ﹹh\zd E|U ji  &ە]CT{bC{W~-bu;>#|Dx}r״H޲iy5$$ÿ7Q_f oҿ#>&~>9+Zգsmq +~ ?~s_q0Zw/+ngV,+kpd,mܛ"w=/ 7*+k"i1c @oG?/MSF܇61M$l76w65 ?61Y_;ďW$2e*pA  e9k*/Eͯ[?= G6p濺ߢ>ݟ I<jgm7_^xkAa51z_՗#ǫ Y*揼\5fTq2xz>Ƣ> V^j67KiVX_Ue$?d8E0((((((((((m/*/ݮt[~2cLK[ܬ?L3s_G-ŤN)!t9>sPpWq&e~7B8ST(=TRvQ~g>~~88=ڵX2 zZ7f-+q%Ӗss%+݋3ORko;Ɵ OĞ%vf5C(/QzWVmYr!8[/Twx҇~r&oq7Y?5ψݱ8[i=ui!iv ,d~"tsr=;W~D~~-KoP9,̳+~F[3,.zGb5J_N~ auRkOQVLlvhbzk$qn ڞ lҜ{>3|Y|o>kl[{ztH׍xO> xo_%DZ5;bEǜa(;r5U:_{ |Fw6WW>bWu_톡>{ͬ\@'(A_W~̿YߌܰZj:A Z4.~ vӓCj3>*)ERʋ_)+ſU~Q_5Tφ_pM x͠ꎫ4&A8< >%+X{J2R^Gyf96.XҌU]$]Š( ((((((wf??Y$iI>[/O[g$' Sj0?GE+'l[8׬ 0k+_81# kN_rg/?+j_I\ _F/kyxMȱ@#H_Ӣ6Z7m x[]QM@M~|E*$'ÿiB?y8qvcF\⟪i_#<_ѳZ.O;8N5!)Vxѕee9 B :.]!_m6N[NOI$'"Fd/χ<}ykYb)MuJlpxWܗ>MBXغK%M?E~ t;]OKԴkkYVXgF _R(2qAEPHQEQEQEQEQ_> ik׶BO g}Oۿ6[Dn4~mm%y-Ksg#+-n,$ՒҶK>䲵}ָzUW<"yף>o9 e*u#e8n;C_< "Ú=aY9Rʕ-e8<UVXꎬR]W$ke(=%Gx! ]}N@eujϋ~./׼3yc-r33) [ =ֺ8a^|ںаJ"Ԃ=IQz2< ڶO 3NޏUWL٢? {Þ)ZDCR@N}S]RJѭe Qwc峋e?.*&14]4t/٣ϊgs@IS js2Ѭ|%V;F%em0Y?ޯnK^~6]Py+6{}K-i pe|vp>ykWŷ r 9 #{k /xd|O:Slm:,VU2V2Gle}{ 1 2I8WK_5[0lLrFni qJL3W7r|<$($r)&:"g_|cm hx|K1ǠM8ǫ K=#?<:59 6(W,yOl|?|yegek|A[>$E x(`t 4{j6J\[X$RUAZrn*-*xJʽ8%9nIW߲W-WQѾ/pXXG G`=Z6>WK,ܙHc*ad]/մچ?&>#]j6+ե~|c?覯#Wb>ҵ!kiY¶ĴϷBkֿRhŸЍʴޱ?|Za#՟}?Id(?R?5/_f<^$F+IgEO ׭5}_?g^_z9_>#p?䂊(d+টd>6/xɐں_u$a^*~?sh?*~Ѧ\U]KџvE#,?#(O(((((~ʺ'|s;FgC$e`820܊aN.u_WNU*Kh97薧T7U7SEmoY\"F$~Up֭I=Ÿ åMpKtm}߯ڳ?!5Ǎe޶RIQ_)%/vsr'bL*ٴㅃ ]iƿ+_ $77ydgQcO܃?khX| yG>]޻! M_WbxWJmAy/ 8;&_ߓKr܏~!uh|*ۥhs x?|xu9&wig\sZ2*[ ,_F uT'E^gf5xsM)ry53lIޒrrճhХIrҊV >'Lr `aҰIPѧUrԊk\~ߟ| t;UOƱ5KעJ̣^ F5-W-05]&4%GVSg5G3RY/>3߫Iմ0/=tނn2*?_<)"mNt6Wa+>=Spzpa[M}_~AğF>ǧ, ?x6J'E~_V_֐kxÐHYTR|ذ3=Ti}_ZMm\xmV2Wn{[p`sžyomBG-׀Mq%Cۧwe|Qj]d}]EWПQ@Q@Q@Q@Q@Q@Q@?w?)p)1SW} |>_yWJ-͖[!eI .k/ӿ%JdxTJWequaۑ;s$~mmsg\׿_/G*й_&p?֙Ͽĵa>-g*йླ&'s|ѴQ?7=Y5&gKI(I淧)G6cca78~)?)>:I$gÞ+4 鍹Lٌ*kOXoxrhoY8{5T~'^"y!MSE}AܞluҾL F[_F7GY^~u+YC_ Smi?-->3SJ2EᴳqC b8QUGA[c/aU+nglLj*qWn˿+>6?p w6ukM8}Ou.s#q_Cx;]8ƕocd6u#]ϟƽ*&GSXH&\wiml!QQ*z(#IYlgUojzm1&\}O_!?\>3 MQJڨώf_ʃ?zoKxHѵ0Ǵ򞌧) %r xc㧅dѼSZmEĶ727r8{uZw*UI{ tyG6򟒟i/ً^G.䗳+Rdӏ[W\Omc {\8YI#Q ?gtF_f웍Ӂ'P0W#>jMg:fa mA$Agf4wqaR'Kozg΢to?ѿi6Ũ, 9G>aPVhssaϞ5QXQEQEQEQEQE#6I=KRѴ6ypŠ ff<I_R-[|Lo|M1_+m(ݶ[Shj |y^Ӧ07ψfC ?Xp5OD,.M[Tm--2Kq#P:8u$'ͭߒxxqA9ۚoQ=9"hO;NH$1gv9f'Ik;ֵW*$R/wxeX!r'߳$[xLJdf&G"YS!T`o~J;7/31*O-uqz?JVgw O ZD^}0 Q!a_NucBc@*z+JxъG6węs["u7oE^J(<@ևeM2k-Fvosѕ}jod l)!:Ĺ+{|H\"_Gcs >i% es{l ]@Zˢ ÆX/,? \=8x+zu[ݓg,_,&ӯ"H'đKxr<+ q]%y+o™7LcRM_;;|,n3=맫2+¹b^5=2EԮ, VxeBBHee< _(c5 歫]z3Ouwu)k1_f2Zj-|isy|;W&#T#$| ,i/w7<-fI,0umikޓb'+{^N?ُ:^/'U%ͅ=.@;TxP[Kchrl$iOvby,If$I9 t_ߗw̜{ꤨexL?NWƻ{ז1ৃ a ZGm{P :I+#rYϸMZjrݶ~QEQW|s~M w4BlgϋlXj+:iՏ%H;5'[UeΩm BRf+ 9s_~n?Pu=&)=U# A"#/&9B~moLG!F]L.~GχIV8N'IT}c2[$O1ݎ|}p6F>=_]jZ>H1SH#  >o[j(LB-X3$gCʞ:omo tǞ'gh*{q#3}ob{ky|ן+Iq[p/\y]v-ϣEex#ƺ_{kYrX~wZ=4RӨ$5aES (((a9]~W?mz02LG0L#_.IHx?c' ߼}RX8|awL,a7.53 jT-2mnϻE1`_?j/ j2"8Q .}?#O@>LZ9fb7_/a/m-~}J_\3-G#~|'}qlgXK6hoฏ]2IFox$Qe#֧|GfhZ}֫joy$^I >?~! {H|yrᛋ? ޖ;~e| CI*o?h?Yih|:4Mr002\(f_~> x{ s_IbA,fNn9wm"_O*o֫SE{/!GmS EF2ޚ&|I0xU?jndds 8}z7ۣÎg0z杩e#Z~o.5ڣ¶^st?dս[/ů>(xZQP-+=p`h/٫Α/ ] ]_Gz]Nmx_GRAy GE~3N~8"KoZ\B?m3ܲ8J%Avי=N93l<=mskl#y;V!T`x->$ ,$Fx:d _ 9?6:'w^&$.w\#]j6+]{o#~QExaEP?V?4+ ZF-k+ &yaKO} ?WHO*#^KN?_a/;Qj8YDD( +?l5/_f.R`k|/3Ob|TzsWSFe_ףO#<7 SNH(B i&Coqj)K/z%+_Mf/]';ƍ3JgNwg_wd_2R?i(NŠ(((/!;"x_?A/JvF/#*x "KGnf79iY[ÿ| ao ֚އounVT` b [ |F[1-H?4)%+ <#Á_aEL;TqO_2~gt,^ HU#7f-Eq_ ӟ NotR<$y֒ oU  A=~ qSg./ _ ^xlL\'ԓVik ( ( ( ( ( (0~)1SW~|Sc?覯*|S7+ OL{2WL{2WyO?IQE}xQEQEQER:`:@*~֟K |`|1̍ . AcTh^ 4VMo0}#R9 __O}վha>+R#!ʳj!=&/)O1 +HmvkF-N( u xᛇNl<߻:_~4nw&i-L\ 6##_K'xI 3]٤op6rn>k?+˅>e'-[wo/袊#((((+ eu?+χ>+Z9Z n%<1&)~/+/~%aSiAr=Tgn_7UUO#?GM~Kazehhx]4I V {xSt;ֿQ?ao#Mhuv85Fw͝jØ[4O |݅#|ek@|aC PgH f=T|U=}~g˩C<6껟61_wO-_>NjM2[ٱ:?=`۴ɰ6+m9'< = 5>ڷ!1"_͹)邾>'V>O1$X{>&ƿ;aTw,+Y~/xƞ |CxRIXA"L TQ袾O3W^.~yrpto´{J^j?OFZ[9&g h؜{Ws e"xz.`p?ѣq|?G O ſYt? \}DUj 3c¬vAf_+,(z?_yI/jμK+u{w췟weQ_xQ@Q@Q@Q@~sk1C|CEx? (@yzfJXV +1RPt*sx'1ͲtzN/xjx{׬M2{GN.nar[ʌHA_Џ?/[CXj썮(8vۜ^?lkz|,u,|?hY.$[;۫t*w`R<1x+zNciiztKB(mQ| dIʳ^n_&ఔr9׍"֛g{s[HzQ_f.Q@Q@Q@}Rњ'/_ƺw[hm}pE]~_5zλpgz$QNBu?|\mI~|H|0eX>=xw.RZ =cntӷ c(qk GX_֋ ^q.ihUyI)s%t_dS me?q9_ە.A\+W6Zư(8Q@ + mW=>[A[[X,@噺b{I_ue4}.'^#87.q Pkd(\((((GR>!c>K=G8eܤ8#Kŝk(&f9T*2YN9 8*7nֱ;CvpwWJ]ΜK g8RFA_lt<[\7yNmR*ww~m$@/'Pm`bLSc؏7xVͿU:pjr'jsܒ+pHJ~
    \FiRtN׿ۗYom]iQEzaEPEPEP F5~_e>(H4zMaݯ2w}~YŸ23HHڊ((( W#?ᯇ-_CѲO?͟Yc}ag HOce~7-m-6Nʼ ŏ]_IXJ_=}!wY=,ښJ r՟#WO7+(w;$k6^[-(wIw2%~{W_F>< s(P͊60$5a:x _P/v&<}*+G}&~?l>?Ѯ)|R4S?;_\3]]Lys @@}g뿀&D69kĚsFF˘ۂ| E; 2t]'w7Y[\cQ<f ~wi g R>IonDM3t>_?dƿ?h iFu Ne+gFOߕzYV=#ɶ[P%.X2y?bU(EksneڧŞx9.Ib>Ylf% ڧaFõo: nu~#3#BR Aƿ3~L?'OׇHSZ@# r8,!1kxH59sGсzRU M;j?(o3W<_DÝh*aVy~_0Gՙ`۷^~,n&Լ+]7Q < $hekw{FJ3%>kZ?K. ǢN``y{o(A)P>̱+崉ΔH>&NKѴ?|3/95YkKOIY^D"=#Q-on +ޥyQ/K?~Y59[QzQ4tWQ^é[47k~)g߉+'ܿ_lSߺ8ҨE+*Q`+ipw\u~1 Qƃߏ?f?fxv+ ǺLS)1?c_91xMku+qqef& (4(('~#&zӤ:>尨<:nRFC/g#]j=/L|G`{_cO&%pYZəx{JxZəx{Jo1{'~3ךB ( ( ( ( ( (>3~čjh"4׀uh2q|F&m"O+PѮV.pR}Ct}sK.-/"h'VT`UB M IKYx>첵5ޝ/噍%i%֖%$?K15|6<k֣Q|6F)"T-: ıϲ<>g%kI~*ɠ+Т(({ĭ3ý_ľV۴s̄p3݅t5|ί+lfCW*~쿹Dݗ`&ӯ}Ŕw$`_L+7ŝW_:̛ui̛@%eNy:U޻m@X"׃ {Qم|ᆥV}%7k7+62"^#SL9HΏOC՝f,ݍ}fyXj KFh/x/ygӥ.gU{|R[6t4QE|)QEQEQEQEQEQEbCOaw.#=H===~:~??ٿ}Otټ;[f'˔}@ ̬;W-|7oig w[u.9$}ԁȳse>4$s̥hæyCyGt#?%N~P+WLn-C$x~+A*3# HAkj2wKeL1"Lһ%]F|oz3\^Tj?&a+O頢(((s~x[e!kVUb?ab#ocl+^ ~%Gu]v>/4½ s})Hòʬvb*: $^]2q_\fA}ǣFjl*[IJcjG߅/k$Ԩ_m~O G m<=b(@_,I!w>]W4EB hX]l^"xD6&maEUEPEPEPEPEPEPEPEPEP\Mj_㛵G_\C, d+F*˶OjrjAO& E+Fda?5W R-=^>Þ8ɰ5&*䧈ڝ̷q%ħ/<1wv>'_o찾 =Tԭ_#iS2XBtH>)_uOhSu4T?,,h?a_ҏ/z𖔻t i`ā72}I5\ؙbg?7'[pX[:vv~I+(((((((((((aJԻKgb? ҄FY 2 _3_I>wxc\c$ڇ[G$EZ$mO]g.__/ht{ܶ[| 'Z#c^_֥*5%N[c'sJ9_G0Պl7o90|AdqY-m݇U6| ޹x+ uIH+z+.fz|oÿ'mLm',{=oQE!y)|>>3 opui\D d:( $|cm2'b)ȏ-'] y7iɡ^RB5k__V?4+ ZF-k8o#BQg~_w-_ ‹~WLJ>$!EW^ieɩ|B 5u柶W/[U/ȣ^"?C?3@[/j/_ZrAEW~SO2ۏWWM?|mn?_m]y?/^:k0܏z?e9߇?4iWpu~?sh?*."pґIEW'vQEQEQE~=~eWtmM+ ]@P@BHOZ!?eo8"V[6}^O@1_լ7RA?ѿmp.ܜ?2:tQ4"2X ++{e~s4=88 G5 衟\!SgXr~|L 4}wS|G"5JQz9o'GqCBGmȿÿ KEd;?ܷ1JA ¿Ne&?*&׆ :ޫ@%vbD=ݨ2p]GO)SVTx{m_d(l(((+4/IizgfOCA#٢I=)U)RZiL n|g}w鐫MuyQ6rfٓй!GԱ4::0T j?qAK_ҭ"5y2XFO.0/+[x yקqMNe+FG=tuQ_!EPVv垧\giӥխMH%F ڪQM6D*IJ7R~__yg i&eҙ+z i&eҙ+zA$_^i(>(((((+,±߄|k |ʯݾ8̰83B(x; 6%{Uy++:XKߡyDs.QkXz&g_Će[x:}FiSp<ϰvF~hڬk}nvY̓}X0E~~"l[qkV _w9Oѷ48̺Of\+p((;G EEM!("|{^7uRS6]Iw;vN+_#t?KA7O"E-KsnRţGs_,x-7\_ 00k]:+$xgđȇ AQcgLLn U+CU&C6?w(gǯ~J+EZ/HqoVǶ=k BN8e,f/ I>髯((+⟍i~#g.R}wl14>Zޯ7 N\fZ "D#qʄM8w/X !I/~=J}gRF#%k? Xu .?F]C=x6>9f/v_w(G*x*z{jMv*RҔO|+ ( ( ( ( ( ( ( ( ( ( QJoܣEY3t+K#9 ,YJ*u=Sߟo-wnU|VqF I~ ?>jUR_£+zQv?F?; <_ sʸ DD #W ~I^ #a'L-xhɌ}{t8<?6O~y\f҅8GO~EW!EPEPEPEPEPEPEPEPEPEPEP F5~_e>(4aݯ2ʳŸ23HHڊ((((?Ɛ׆ϱ%d~Qe;/9lI*ڰ?~د<<#]j6+]{o#~QExaEP?V?4+ ZF-k+ &yaKO} ?WHO*#^KN?_a/;Qj8YDD( +?l5/_f.R`k|/3Ob|TzsWSFe_ףO#<7 SNH(B i&Coqj)K/z%+_Mf/]';ƍ3JgNwg_wd_2R?i(NŠ(((:4by,>Lqy!>}cYs7 _J+P1}g oUkW9Uvu}}.s sl|5=C4mQzO$訢#d^zZNRmݶm[aES2 ( ( ( ( ( (?__ǘWO#i}lp0Πb:(7k(xbWPXc2+Wbr F5'e 禽zG=\9|\V&mI[ݸmQ_4~QEt>'_ilVz 18m5)O^6𶛬viD_=~+Od.:hSED? 5VWa/z9zMs+'oPQE96QEQEQEQE`Sc?覯$ M_<-T~oW՟%Jd%Jd9y +(((((#Їg_m.: r`z͚> -ܰIf⮔fٜY_VQG~f/Lr%se`oci>}VWS_e~oqޕ%EW؁EPE߁)6tpg#l@ddT %|f*}-pǷ{W}~q_E~#nDw_?͟QϏ3/Q^QEQEQEQEQEQEQEQEQEQEQExGmcэ_nO?w >s#_Ư_7kL;_pLEA>+3 ( (>o8k W#?ᯇlƟg7XX~x챰iyÿ<6|K _K_?f].]'m1?1MUe_P'~1½N<,~Gx$n֧QE㟬x?LSO2ۏW^_OK>W?_7#^gNwg\wß4+K)z3ȿe?~QEIQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@>T/#a{lY]"QqGQtW_q~:>B>kYF}|cU0>׬Zt#; ߻((|Ϊ(+?ࢊ(o7#ǟoM+ҵ{]QW? DHE=fEǿZV~[+290*:s_A3*~w_?\ I/HEWQEQEQEQE`Sc?覯$ M_<-T~oW՟%Jd%Jd9y +(((((8º$-%$! >;j@+-sH[v]5yr㪪Xjer? h_e$O#Њ/ػK:?#o}AyB8SwڕN+Op(??g}3@]Qoas íw4mZO?vi%?܎#׭_wg,KZ&h=LjM><˫Q_h z0U {}wMiMqgF ךB /3rP^\_pQEQEQEQEQEQEQEQEQEWU~ʗ:i· @l|?ξg?xzm^ObK6P߁ фk¯f| 5ɱ9sZԄN?F@J5_?|EWěI>?mJ? ? SHfFX\Uo$g(/IIK }ƪ/?ٻBJ}MEWßفEP_,ht38|~T;Id}҅ gmlVc}M^G{#~tO2i5{4(KM*őEq4XƬ1rI)ſtEu_Gᖠ$š\9rZ"wyn qqt}\3oq,*PWEKbjS Jy W QE~Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@8|7a|T!mUVO˴5_?(wXW0jp0$E#m 7K_ꯢ~5C?a+n>o?Ÿtw\?tyt+ҿݟ.JFv#zl~k>ϖvYHwڢ%ŅQ_D~"QEQEQEQEQEQEQEQEQEQEQE09XcW/&SOǯ1 )GA)#/?otL:((?3?[zo8k$qx%7n_+6?O~&W/!> ^_|YOѯ~lh((+>G,KN$뇅 ]P9JX<4t՟~]Zcu$3FM av x>*u򯴛-F`WI£//N(ծ4zgY;ZJNXפ-G:+l ݧFm_/FthiOt_XkVQ^F3CmA+$/L>j^u߄7@ˬqA6}-}q_cpyR%s zWK$QE}(QEQEQEQEOIs<sWi_w?)';دqvg_Z?~QEQ@4XЯ?)iԯ+-?#_7_!?䨏z3ֿa/;Qjy|aEZagGb+耯4Ծ!EO+MKnYLJ?QsY_SFe_EO ׭5}^}?䏀?H/O9 +?Y )K+টd>6/|5׊nGwß4+:?e9߇?4iW~_Rgݑ8H+; ( ( ( ( ( ( ( ( ( ( ( ( :. 6ձYkW6砚@~U=_q2@e; in'کQeOrG$3(Ə(+?7OS$}|_z;~پ)#w*ϏI p#^A#^>3׷N((((($ M_OIskx[Oߤ5?8?KO3/_CKO3/_C?u?3&rOHAEWEPEPEPEPEP^3hwyym{5A݌D. {5|k4rb}kRkUOX>B?5ݖRq>+le3ķg?q~2GM~|,ghB+K*6q*c7xL f ^&!¿j⊚ӧ>ysTps9~q (H ( |g y㫽Q:z碋uXٌy_ױS\L!II~7J[9#?zw:_192}Ko>17G狵⠮Gd2>\K݇kV>5xO7W5}SZ R+3ʜix1Spg7oI%QE䟩Q@Q@Q@Q@Q@Q@Q@Q@Q@ÿګZZd1ω` {WпEO:ƥC"`Ǿ']_|NYjj4hefY#y"#U? ?#X:iT*eWkWj+Qg-Q_!EPPZFJՆ?Pjj(m;_~6Kb *ۅU~C{C^Od5y?xU$V)ʈbb_`fq=m|g;Ŕ׿ >ʔ+ʳ+͵8/ڊ(ְ((((((((((+7'F'(m21U+Ak#1M7sq0Kҿ'p|CIigJoW>GQEQEQEQEQEQEQEQEQEQEQEQExGmcэ_nO?w >s#_Ư_7kL;_pLEA>+3 ( (>W~.5 xfMF;4D2pkt/o $UwEzlB Yy?f3hב⺆w uksl.eMr9S㊭]08E.yxSb)FU)2i7ޫ~|/Tw~P2I?$_`zW<oOv?^"DCGAAMѯ5lnnyD13_Ž+c?_vwctocq0*ʞyz*oQ\'ǿz<;s_[v?y3F㳣VH5>iɡ^RB5k__V?4+ ZF-k8o#BQg~_w-_ ‹~WLJ>$!E㟷oma~گ;M^^H=(Vv;P+3!Cs&+ ăwp ;爣#{u+|[a/<5FXZ%B$elwE_/|L|boj3޳;\]\yv=P*?-M~%[x_i[i{  r+hk稕HI]=u? ?m/n.<-[sk(& 2z?~GX4i=% M>G¡8j3Q־?|iR~ռ@=^ދvЯVl~ Tۓ2aaXxlI}CH g)_j'v4#Әޙ  u$8\ $Kb}84L\J2^R~&le;BU4m]$WAeܡm-OXuz(4(((((((((*;Xdx$r(eH#IENwov7D3.&v+2"ѵ}#S φוxմv[jj0r tM:Y/!H/d@7Բ/^Q ~$M^sm4,NQu9 r E~OS'ZKݽך{g;_}G5#*|پhgE|-?m.<1Ql0]i?N8\MQEnxEPEPEPEPEPEPEPEPEPEP F5~_e>(H4zMaݯ2w}~YŸ23HHڊ(((dWö?"Fi/ OP`a9W?'65GF{_WeYV*B߫MlX )”l`xE\[ݾ?O W|P74"ݵ}>pnk޿l Wl: < ׿s|>b׻fۿuQE|QEQEQE}`= ݷ%mVm\(>>Af~7Z^f RM0q C^I8ii?-b?|~Y':#Ȭٷ:úx/ڴٶ&:l5ڱt%ŲѰ1{{?ϾR6RjE1Dp~Gֿ.kg ֶw&`?vE1-3rQ_ɐڽ i&Coqj/z%7_Mf/]';ƍ3JgNwg_wd_2R?i(NŠ((((((((((((౟ Ʀi?t𝦯 7l5\j2.pe,{G6NRw-ԤG._ ثR[O?>=*3;iS3(8?({ WqMw.?|\O_ ~^Y 7"m8yX#W YZ^Gi=V6("TWFbEo_GXʞ[ɢ7QArѢ+sl(((($ M_OIskx[Oߤ5?8?KO3/_CKO3/_C?u?3&rOHAEWEPEPEPEPQ__CYMss,p[ۣK,0Td'KssM"EJ]jI<~sDࠩa'7.m KRYGLA>Qw`01U9!W8| w}IWO|]sa,º km*3&#UQ4'ߴ_kV߆/B).?єq_+| }WW4DU&[> OO`?eNxvХw1˖s@TuFy$PaU ;e x׉'(Koi%H+uGQEgQEQEW:ok?0="N~c $:Q>ӏk7^~HXt 7+hpNTq}A๼? {ns&rW ғעQRjAӚ{x v#M¥6-Nf3U(XFyI'#>8 ;AB"7W7? y+ 2 dgp)WH>!km+z3hڛ*Mrbc8% ~"|;xS۝'Z'kk[:C$k~ j/?]ח)US3Xl]*쯪ߕ2~ɢV~$u >%I 8e V cc t&c 9hV\h~|M>1"~լTKmwjAUe r>ᤖ3Ŀ s^,R'{]ϼ_ݢ+?2 ( ( ( ( ( ( ( ( ( U<$~' X>--$PElB@3&82qUXgz|[ݬ+*0 Õ AדP>S Dp~s}+ʔڰhz;?ٻ7{K>ͩiω"lo$yѸ# CGgWjxOM;/ٯū ƕ9unF) `F {뿰#'UV.68MxMi&PysD}$̟ć U1Ok̟ĜuT:$NkWt+? 3ۣ9d]QԼ?q(3C`yd HЕJ5VY|Y&?(O/̩:u`>>]5aEVǔQEQEQEQEQEQEQEQEQE09XcW/&SOǯ1 )GA)#/?otL:((?3?[zo8k$qx%7n_+6?O~&W/!> ^_|YOѯ~lh(((*BoY$IVSE &Q%t|P׼3y>}-r1檱 ٗ =W;_ba5wFG%-(sjQ=5{ǩmqA,^i+{U}g_@E+ 3Ē ?KoZx޶,Y.dbK s\mIs3M^i>h>4ʟ 0'XɂXrgGۃt6vpiSkE?wjLq8d=*_]xX+.7AioOp]c|<O84};;;th09{y$y5XwsT|cBkֿRhWЍ~ZI?Z|aEZaAj#O՟}?IdB4Wм%J4:2clD2{ʃ~V'?ůjZ=ݼPG ȯNjWZAsr,#ᐸ Trp2p:?m_b?9jP>3`̼r08ڿ>Jx'gE㉤h.u^*?,7`8J m2^~kzM֟ ukyeU;ܟ_7 O_u>!Rx5f~Ep؏ qp|q,?Cj1m$uT= |[`kAK#ᭌn6`A<4-~Z4K=7OO-P(TEQ7и.)K+টd>6/_}]۷aʶ<fz?VEKy{);ңzB7&kQ^QEQEQEQEOIsk .E5~SɿI_j~p?Vf^)?a_Hψ.uXK9d`iPp^cC? kbjJ4MgǼ9ƕ4ӚM5~hZ57cC? k3>}GDn_3j+{׿XG=k,o3>_kϥ^c!|!>fb"7 }/ ~ce6-Zl@ןx O<=L7Ϩ9'[C&h}G{pѼT}^o'`]nۺ=2؉LFfr_ि~*oYc/Eɗ GiXY5xfM/3%FP,/穢^Nסq O.flwDəogq (;xoxĶz>csjM#ROIW߱7itaĺT;R:GOVЊQC\@>oUAȍ3#%zX 4W~xsڙ/zSd/G>LDMDsEWb1+u*;edY '/N{VQEbzEPEPZ2ͨHl?Ҿ>P۾vO]:6\׎ø8rn+?g{aO+w,O_?KӃP_%3Z(?B((((((((((ceo"ZFڥuhdk)qQ*~EɿIZv*wE8gge,p{?}_2%/G9l#q035l]OV~N~:QE}QEQEW̿Q&no*M/X̼osKDIJVjW=?yYQӫ_kf=?|W6F𯌴{X9 s$,8dpH_gboz]HhY{D>eI 1??_tX5$G{HoA mW_\E' kV0kuɋɌv̳<nnxüs py:sO87̟kgct<;'rK[t0,1|Lim-eXrH@ ,*Zh_-|qGU-Tq!n{}%ۥ{YOBV2~^~#8w,w i ?yOI/)Z^rgEKړV7trP캳'3Mz}:8;'^Xl]7Ntqi枨(((((((((.| Y:&{y8Cz)O ?W iؓ\YӅψ\l  #g~>vZ-4?Qexaс F xIG0? |Wx7͇oߤޏ/gOK2 6:ޅi(S89__sLdv>i >&-wҠ712Wi9%'󌿯?*RdEokRo_PK6!ҭ.o#Y-YbeYYI r85f/ =3,Ԓ/j^y7il1n +;+ ӧ_xl#hʋ;qo? (q;|KZ|G3/\4c2pZ~l}OEWQ@Q@Q@Q@Q@Q@Q@Q@'v?o ɔ{ ?;k7jv|Qcig _!$#j(S?΀((-_C3?[zF?i63eW/!> _g HOcח?V~k~:(4 ( ( ( (2w@ RTR+>wg]eaWG|}?v:X^Y+i?y pk8cxW'#wE_Mό_e] M(}Cyny@yGט|!6uGq9%G״_6_z+@((_ {Mχ|ak=-ot 28) 3w\d/5 aa؋B{,Qұ<_7[l >*<3^źc}e{HFϽ}¯ Y>l4M6["1߁ԞI$MlIƒ[QHg?V?4+ ZF-k+ &yaKO} ?WHO*#^KN?_a/;Qj8YDD( xD5[MKNqku zB+όBu/H|4A#=G}Eakx MF? k 8u[Xp q_^QOYYCYEom V (@C )K+টd>6/|5׊nGwß4+:?e9߇?4iW~_Rgݑ8H+; ( ( ( ( ( ( ( ( ( ( ( W f֍tbh7gVV<yC#DW+>k~.%ز4 V;GEQNBf<g!~?5네%8Dc^*~~?çg6 ԵU7|K'uEW'*QEOOjo߅})uv0dArV {4^%_D/gٸYOc"aɷظc)xJ q^v~S/Gj*^wyvKVq (#8*Ơ`ڤ.[oVQEQEQEQEQE`Sc?覯$ M_<-T~oW@M{gӦ& H8d\M,¾"d8ǕYUvqit?9_I'.@H-=w;p+鏃?M/eM*_QaƲtV*H(gҕC7 2U(aO}O$2- HD("".; }W~(((( W#?ᯝaVu Gp  W_Z׭ | ‹}_"v_;_s_~S?a((((((((((Zy c2M $ cUnv((()PYBoí5]~QG]z¿Z Xm^X t#__J6ƍ<F%<7}Cٔ=|g.gT}ɟqp8?fgQ-^[/.h7gſ nm<%i Ѯ&{wVՀ`x WE_SxSpHDﵾQB~G#9R5 j|J|n񤸍YWRNNq;LpSO~G:ں'1l6èZ"DHFN0ynBh:uct3s|nY7/*UcUٟ߶CoZ6/×!% hnO|_E|`~qh¿To6K=[,M|iZn`xQe;=8/Gq*}J>8c^34ֱ1oqǀ Ž E~b/cMV28G'ik&/khڞF=K =|Àз b@<)n:Nwjv77W `C9  ЊY?-&-OOX_liԖiYOVMg}C#?a/xo W&WG uR^NŽ2c$T|XYzՆ.azXuVXв zI[S+?? ( ( ( ( ( (?O1 )GA׎v?o ɔ{ ɟCH7:GQE~EPEP{&S*n-6}20~??a_~kGOz{rq\q9 eѣZJ񋷣<|NmQ+SR4m3Wca*UQ+O/ ?D;}kM;[he$`{"Ju#M9Ԅߕ'+# ( ( ( ( # /sȿǏ-u:5Ctp'y~e얆njWis]f'baQgÿ|;^|}o[r3񮾺@|bKvJnqF\)N n/ψD5ـ _cp Rogs6f%-tU x~ӵ}>Q5mݴCsM;3(8=PQEQEQEQEQEQE|cBkֿRhWЍ~ZpG?Z|aEZaAj#O՟}?IdB(?((( i&Coqj)K/z%+_Mf/]';ƍ3JgNwg_wd_2R?i(NŠ((((((((((+,5d߅'>Ŷ찼Mև*'ە3.7O FUcxWqARrޥGo$QZSo. |(o .!oR Ǟ2nϨkofn0'A5Y0O&$#VGU[ ݾz>m( ( ( ( ( (>:k&+ E9UЇ_2ƇoZ_Vk7R1]k?n7{1T./c c5_%/͟^$ڗP%3(?B(((((((((( 8º$-%$!x?w#`s _U,ڏ?Ӿ#ʣ?BHY}J?inw5;mc$^HD̼~ +S՟sN/u0+@(((((3Orh7 1QnF7 $ gELj\]|-h0p]ԢiMjq ٘X~K`H: $ ~W^'džI\2-ᲬWĿ{}c],|dnaȉGݨi @?哜VN3Ư _Qb[/灹Fz7S#yVJxi?{ƿgY3m"M6rkE `<0Rgox#ׅ:j=ßq};dRTyGO˸5?<<8 +s.Vkhhſ2+?l ?1PӮz\ϗ*x=U :r_ҫ U)?3⧂tQj?QZAEPEPEPEPEPEPEPEPwv_43!HP"<Gj7x7: &`dm;i=zPM.μnϨ^3xs̞.xv^^NgU{9]BEs2)RDiIo~_/c gZ̖+)̖:,a'k >>Ξ |?mkZlh֒cHd4n=T2A"H\u⿇{o<coa*Jiø_Y¶⺭ׯ7d\iC iFzZҫFZ2> e|qm `(cx 0OxcCgizfLbE9 9WG eJGa/oˆlo#OD89^쯠x8'3rH9Zʞ򦻮_xEGQEQEQEQEQExGmcэ_nO?w >s#_Ư_7kL;_pLEA>+3 ( (>o8k W#?ᯇlƟg7XX~~I+%[io&tQEEP_B'/ 0~W);ېGJ'^kK ʓkrm~fXYsh|mkk 1(TaU@{WK%E.~GGUþڋ}==:}'+sh(((((($ M_OIskx[Oߤ5?8?KO3/_CKO3/_C?u?3&rOHAEWEPEP_Xlt6p#R*?91ImjwK_Yn2׉;y}#2_~|n[i.[ݢjW#>Lz91⯈?w?_iz-o}IksuDbABxy/r?Rp~i]t _\w?q9 Ox~T[J;iWVPE]?a| /i)fXH'k1wB>\waJ[Tmv_)&(c((((oטOjC>ox>𯃾j3{dխgѶdn}+u?Vq0~sӡx̫kX"`ބ_}{_6bd iVO* 3PMWM]K*?O_q&(aEPEPEPEPEPEPEPEPEPU'+YY|9~[ȯ{#Aw98gk.~$ 3Z_-Qgm[2 &QIr )B~<3N|'<uHZH3hD' A yÚ:T[>O?1!T+7S7[5~cV,S^JIZTuE~_7l|-q{]G4ۀ% FR8"?m/ƻ 끮eƑ,{b-rBGL[c9nS k%--kK !jXhJ;Uoe]xW3:M7^oݥ'1DO_&?P՚ѧ( ( ( ( ( ( ( ( ( +Y 8d1dR0ARQ@&Ӻ?'??G&zZkɡ{kð :ԴcNz[I!Y{ __Y?%|.o3xI>]*G#&Y޿̐Gpq'('->Tls\GR~*]7~OF׏xNb ]FHzʿo xPWu}&N)-C+ Wg;t[@g Hv\ IX:|!gQH/V|EBjߊڜv2g+ࢊ((((Maݯ2w}~=xGmcэ_nO?w >,O|$?}EWgQEQE|zpF{_W'?o,p $'_x2l Wl:~Cg[EWƟEPEPEPEPEP%tx@ld6nˍ?@W➧ϢWwQ463Fcu$2pAݚUTjPD#Wm }|vH+xgiʃ揤g\:%kuo zc)NQ9+~_"[ag좻 |eꭕ>k{ǃe-sዿZv-?ٔHOtZL7=Yo?6>#_TΪeUv} (?(((((hWЍ~ZWM –Zt~?TGC_( W5~<_w-_q?O1?lQEG@QEQEQEWM?|mn?_m^^4!}uTĿ3xIUr?%~Ѧ\Uy,9LҸ—?FXJG%Q_QEQEQEQEQEQEQEQEQEGww$p $F $wmIM?u[m;Lӡ{q[ƣ,ǀk %e92ѲJSw2@~Q?\on|G2C׺0~s6)_7}a&w{x=8y/˸%>&((+?e{Ŀƭ3~"wnæ)eğ@G,+wY/~ujmla41Ա (&{?v |M2?"źKSU_(l12!$(=If X|bO],]T89/Ozmv'p9-Ѽ{o#MbJy׳dSݲOa(w4Q_SqP[v3_^xLMJOVշŠ(9(((((( L|G`{__w?)Dž /MJ?S2}^L=|2}^L=|cSO??g/4QEq^QEQEg (f(< ]ŅҿMkz̺ݬ5m>$A^3"ҽ|ջz?/ÕS©Oލ׫7/^O8~ʿ~_͚~t+<িTQE|LQEQEQEQExO@:_-.-Vii e9M K DO0B̟ZYބksgXlWIe'#q'<gs^h2F0&i^!7%'2ZC5Sȋ?{}|*gW c>1KӄQE`{EPEPEPEPEPEPEPEPEPV_ C-mV 3Mߧ_7~x'FsɈ&cxgOWWǯ2'm=YcxacN7'íSu#UEmݟ۴iF8ӎ%QH((((((((0m߀7kaA+8 eW׌qWʪ^QE(QEQEQEQEQEQEQEQEQEU}WJt+xn"h'dѰ*x*A ERq|~RĿ4x{L?g2јh. $d$8`oP?iŐ4h0-ػ0DiM~@d?7g(5W̜}0vs\ِW٪w:seyvr*xdRUA{WYf5V|]x=X~rWU5{ͧJĨ>T^!ھlqxhb#~=W b8s;d؍])Y?2ŧQE|QEQEQExGmcэ_nO?w >s#_Ư_7kL;_pLEA>+3 ( (>o8kxb]4[kU4#8 zMy'94u9fs*_?|Gq'2Ӌ774z?4*$'_xs/iooxf/x?JѠI`l᲍X 'dsʆ*0T^>bjQU#$McN(?B(((((Q~5E|v$rOf[+WՑYFFj YqBHI9pxBj-ȡ؜-/)oL6qv|b9T(N׉ѯ2p6@>בxihZѯ%rVl3$lVSt 镩Ƶ't9#'c Rӷ^+>-?^>6J.79VǶ+jANhm,f.*EI?)+((((( &yaKO~XЯ?)iGC %D?9 ‹~W%'{ / ^G?T8ȓ_ȅQ_4DQ@Q@Q@x?LSO2ۏW^_OK>W?_7#^gNwg\wß4+K)z3ȿe?~QEIQ@Q@Q@Q@Q@Q@Q@Q@͵rxOjV|50_-B6и3v  5|1 g\Wou ܪߘq5xW~__gCOTij]=>'QE'(QETnqjZZA5ԋ 0…UTrXMBYI޿^?K/S?>"i˸ĺs FU?~~rBzyVWW_S۫쿭rf8y)ìvKyKOL?dYm5p$S]ݹ:y;%΢QVK?)|Ès:g>j$F+R/mQ]GQ@Q@Q@Q@Q@Q@Q@?w?)p)1SW} |>_yg i&eҙ+z i&eҙ+zA$_^i(>(((|>"LZ]Zo/%d}WGtm/'٧?*^D 'ܞbҽ 7O}9=)$;$Gw5O+vLm *;iG6 @cIok?U+ĸzKVEw;Ez{^?thg/ /`[kViq6%>QqG&OF.M>髧AETQ@Q@Q@ۥ崑HJ:0E~xRx3Z6|*k7]ѻ!E~7'~>5SdWkF@gPk8^ΟulHyn9GO#ƭ9k[6e5L𒾵">y? Icl"&6ky78G .NݓKQEQ@Q@Q@Q@Q@Q@Q@Q@Q@?Y_ K㗆e`˥hhl 3?5?N ~ ah%pC ??~5#c"$V5x+[u֏|Z6-KK -ʆ09P${ʊ3gFW ^Z4ɟg||9Z}GYuM~ߴx^o·ks"/)2>?\Գܰ󴥫/҅(a/հ?񲹾i?]wڈch*,I/џ—e< t]vp\KpQE~EPEPEPEPEPEPEPEPEPEP_\ٕ~ ~'VU-J=1}5i_w ğ؂}~8.o+`*l+ qL^1ES?e/s+ {A?l/Wy/VmH{$\W_HbpJ5$~?ٷ-ˍC#p+[p}5_~<;b0Y5ԩK9|;(< ( ( (?O1 )GA׎v?o ɔ{ ɟCH7:GQE~EPEPE|qM|m_l^4X+{XҍRwtzz=_-o RU%gG|OnOfrU;]FKK=cފ|gm~|֮|Gڅ{"R2H3`q$\UWӿc_*V:KI::(􀢊((((((+ w_Ķ񍠕?ܱ+[ }w쵩_AGR ^>邳15D'Ʈz+ɓʍ>1g< s(n)m-~}O8C~Qxirۯޏ+?o ( ( ( (>iɡ^RB5k__V?4+ ZF-k8o#BQg~_w-_ ‹~WLJ>$!EWEPEPEP^4!}{x?LחSϕ&WMYscFqW]';ƍ3J ^;/a)QE~RaEPEPEPEPEPEPEP_W+_¿zWkZ8.w^rT\+Ҿk_xOu 󒿖5IĖ/~+ogĜIOM%J5/}ޖL+D((IIO_mHKh._Т10.˫ck*4Wv|qYdLVKH|SHwrZ0>sf"2]cF\#KbSrParX**/s9̸4g(|0H{QEQEQEQEQEQEQEQEQE`Sc?覯$ M_<-T~oW՟%Jd%Jd9y +(((3ƞ5MR{Y,ȥ[ڿ*:G#[΢?4K-] Se =W~zbbD8ZiIF !|9um/H.O ޒ_JҳNL_>ߠg̖ +1 :er4sھş٣,8w11i@]ƿIWQڿh4F _OT5)dFVЂ g8Oei~}?0ϗz>QEQ@Q@Q@~uf|gž$DzƘR:o&r|jp|a.k-Cx"3#'rZO C8OzU^c_&Ϗ?|,][].n~U~xC fZ]7q^ss#_Ư_7kL;_pLEA>+3 ( (>o8k W#?ᯇlƟg7XX~O(ݣ8E_ExLCW|;̎5a'dr+W!_JYw6[΃ 6?O#/x2 fY)< dݣ hk 7^GwG Qoo#2(?Š((((hWЍ~ZWM –Zt~?TGC_( W5~<_w-_q?O1?lQEG@QEQEQEWM?|mn?_m^^4!}uTĿ3xIUr?%~Ѧ\Uy,9LҸ—?FXJG%Q_QEQEQEQEQEQEW/ ^Z?yW_dQcVo׼EhyVqCJœe |.L#Vf;>#ZJ_/1˰QϷϳ?$|N?4ֈgOU?z䱹Vճό'fֿՉ/r$r;9ˆVD.#α?TʰqٰDP:(%%ٱٰ2տd~!慙פh!=vԷoI"(H0(((((((((.5?&>#]j=o?~8ʬ-?̼=¿%<-?̼=_WS%}_7??!Q\GׅQ@Q@Q@y_U?h>"76k8.R^E]:588 n qkɫ3KI)Q6(B8 ƿQ?k0s$|oPя_Lœu X|'ŋmp#'O-E?K:l3yzG@n6\M=ھ1nC{s/Ĝlc\~/++gQ_sQ@Q@Q@s<?!Dzޟ5 BH?tTSZ(B)Q&&]J&Vh۬nS5 /LѠMMny /xR'G[I{,P'Ec/6mBfXVKK :SvRri[GQ_mQ@Q@Q@Q@Q@Q@Q@Q@|j^\2q Iݠ=Y5>#s}+3?d/{؉7nݏQEEPEPEPEPEPEPEPEPEPEP^[`Kv ?v_?pw[Y]CŶB?_6ypD$DU,O  vOSIwWN'GZ֭WҴkHbXPPϿbUVJU%%ՅQL((((((((((Mf H'jp9(M#w /n-nvڦf `tX?_6 uK.i(AbIǷ5hbMxѕ{lK;08x~Q~f_'zEsQ@Q@Q@'v?o ɔ{ ?;k7jv|Qcig _!$#j(S?΀((-_C3?[zF?i63eW/!> _g HOcח?V~k~:(4 ( ( ( ( ( ( .oĖ:d_.[̓,B4~bi0kZ5eJjGtyYG2W*կGu~)OS/)fe ʏV*^ZQXQEQEQEOM –ZJɡ^RB5k_yJר~s=kAjǟKN?_'<=?V~p&' (h ( ( ( )K+টd>6/|5׊nGwß4+:?e9߇?4iW~_Rgݑ8H+; ( ( ( ( (ⰵyaC$HV5$xM!W'9$O+_j ~4p] 8P_fKXnK߆ 9"c\rXr-3^Y_qs_ zu%kӥ%DX;{DQEGQEQE~$?MRCnt? w[?ǡD?8'~.^]mg e9Y-#N]#KWItO ![DLhVy˿uS?~* @(UUU @:_8>ʖ_Vgxgٛݢ]Rݾ$(#Š(((((((((( L|G`{__w?)Dž /MJ?S2}^L=|2}^L=|cSO??g/4QEq^QEQEQEQE|E klխa2j sTe_$?WR2:pTپS$)cqX`; ~0~~pFtMps>\3%MW_HEpDZϨ*{/G}h/!yMD-5 :_,۰G|č_mFY[P=^ I"Ek\'2ug=C7zrOqѿyZ_0+>(((+ Tmm!{ ߕIʣ.}k_;τt?މ{.p% fSƿkcK/OS5(?V?Upz/W~(GVv屁*IV+8sQ}?'~'?W/qOidR +> m|%zd~Zwm'u 8<ե_!?cP%ۯ.ig#r'%Aھį>Ck{)}Ii%v(>(((((((?(7dnua$q;_uW~; XNd<j[7 = >: ~<~zDW4m2c&GwzW4:Ew?|P+qg); RkߗwX~~ĿoٯÚ$:Qa7 lzWU*u%w?򬺎_ëBTWV (;Š((((((((((_8KHsy@ q=|<~!~жyXdˌ\Ƨ>'5Sw_P$^k *d`n$?Pg;W1mh~%B<?2@Nqva,s7lY3$煐URjU#H梊+ ( ( ( ( ( ( ( ( ( ( _+KL3mm?W8̦XG^_v./ÿREI6TAyHi?p;e]QT?pQ,׈9zW`yE6~"WO ܴ~[pOK uXF(H4zMaݯ2w}~YŸ23HHڊ((( 7xο|%\kQIryE"eEo9_Wϫ*03'O'sJ*XΥm"˹B-[T;\s،EDc!Ee:+0jUV{ ]µjԜDq{;hEW~QEQEQEQEQEQEQE|'=;fѯH;`D'E|_O~GU_Y\D.5$m YJF5;ofO?xwB km~՟W"0}HԜ/` "AʸK.xW_v]KͤO$d{Ggh~;#+qwÞ1?jW`hײܶ_VK49=7{EW|PQEQEQEQEQEQEQEQEQEQEQEOIsk .E5~SɿI_j~p?Vf^)?f^)gL(#Š((((|~|A2X7N@9W.EkGݛ#>K+uٗO}b2J7gW |yxL.E # [V?xL2ZB0A^x;ĚB]̖17X䍊>|tᮯKɳw~`ܵ)$l|GU(,D~OUѬOH_O+IeQEHQEQEQEWXrZ._'7щjs;7- V\麵F`#=0|.!ɫe4rW5_ߣmw6?1`p!ڭcs`~W>6͆\%ޝۥմHC)~1П/mMX[.3CI- /n\hHn9imr=|9 b(]-liKjy^=ԓI?UiozsZ(( ( ( ( ( ( ( +hkZ}I]8;N?>1Ԋ쭤i(RU I+__#XJ4 YUA5/qɥ*Rhx]S?uk+.^K]<yBRq;n_Ҿw;uo:j(fQvg :_|+[6OKj\ϴ(o;.o V۵3W+#9Q/7;Bql>7"sZQ4"2X 2 ŪiX^N|A8[~uXYW:߫ۿI"r|?,C])ҕ}${=Q_QEQEQTA hwZ{i147WRP2Y݈ 5UxGIqrl/\$,Qb|nwI 6xJ}O Vw)ʢ)5I^'bzHr9GzZ>X((((((+ B/ڋIEe4\9m$"[q_o-+l_Ne'72ءS$(݅8|}T]jڅyerd+#/YZbzEZ>ޤֶ /~ ?Yx Om=ӤGθ?7q_ѥ~U[xſGHf^W%̃ЪqڿUkn ֖w-xI(ch W99L((((a+iɡ^RB5k__V?4+ ZF-k8o#BQg~_w-_ ‹~WLJ>$!EWEPEPEP^4!}{x?LחSϕ&WMYscFqW]';ƍ3J ^;/a)QE~RaEPEPEi-w^7ww25,I]NIB ݾȗĞ$WUӴ:Gj2xI&ਿUSۋ/ᝤ[!u9K#)ggN bk'ᕔ˷Ǘ6r'Lt 6y_qd(((((((((((($ M_OIskx[Oߤ5?8?KO3/_CKO3/_C?u?3&rOHAEWEPEPEPEPEPwg+v,f7Tpq}7!s^;|oo^FNMHk/!#܇~|~卼>n/X,.݇~Cdգ{=?|[+p,V覟-Z$YWFWG0=4&O]?6 fb4͗uEL1=YFTjʔLs9]G25b}תz?4QEbzEPEPEPQ34kp.m%Uoğdqu+k]5,R)$) W~}O?a5 ω~-ܷB!<ܨ?7BvVAG7^κ|Kߊ[^V}'`Կ /$豬z|\ w ƹKǶ>#Yv8JFHÂ?'[_oK-rUu=1/jѷ;[8 r}?^)p)[u_K]~%( ((((; σs06].4e#3x SZ.!O0gWV$R?mta{6x&%?A,~N#~ZI}j IIVtͩ^3I=YgԒM~8?b/P~Ķ b@v][ǰg*9V:ٷ|NViF׶Hzۼd_~̿ ys](\ۖ{`*ʫ5Q_RMn۹~ScN F)tKQPvQ@Q@~5xe=wġujX<ۉo쫸ӛ`Oݍgz^e+7=o~'V[dĐ8%t`FAYba]?Hg9<ǚ*. R]m|A5^9KnV% 68D 3 <_F[~><ı910Nr_cbǖ~OoY'>ֵ#O,l뵖?п<1UrP֍T}4Y-gEi/ڢ:Ov\|y&L`~ZoIbImEu|q̓h¢琈5W*'?dgOE)/nケS(((_Uw~?90 ZƧ| }hΠ n&J{W_Z&,E1Ͽp]۷RG|/򨾽Ku/..ѣ89ZjK>wX??Qؾ+F) Nֈ =eGz_/Ix;Z{sjztskum![y]Xr E~-Zoy<#M3]X䈡(XGA(/er|1 V~?x/W^dtB^X/vK^Q_n'Q@Q@Q@Q@W?V):Ȉo woIg^|7.7K E׬d} a9,-5IWYIJ|hxn|rf֦[DWVXhmSw薒_jvVvYd`=O$I{IF,,I=~`glueOokyW , zGc(lkP]E VS(Rtբiu~e>?U/8Ϗܹ/<޿4`vEz8ӂdGWjc1RRNRo6QEYQEQEQE09XcW/&SOǯ1 )GA)#/?otL:((?3?[zo8k$qx%7n_+6?O~&W/!> ^_|YOѯ~lh(((((((+¯xboj哲Whdю'OFT++I~-φ:&w6YOЃMu[ U'U =?Tj N-w]R2}]RVUƪKz6m_.Jm'䟺jz~&eG[mV12e!?. k#/eȿVnMު=E$_gW7Jgt?ЎXl⹿ĴL(>(( &yaKO~XЯ?)iGC %D?9 ‹~W%'{ / ^G?T8ȓ_ȅQ_4DQ@Q@Q@x?LSO2ۏW^_OK>W?_7#^gNwg\wß4+K)z3ȿe?~QEIQ@Q@=|C.\^^\>A$ W *C$Ѿi]QqsǝVO!ǪEyqM>|щ IIzۊ, ="v&aۂo<{y/T^?ÅxrxJ0_wn%_UlZ-^8Ɯ*܃ݏbя_UKj3VҼ6,H ʰ>ðiρL 5}"úW7xr㪲G}9PwZto2¬wQ~I S_ہ~PC%W~?l_xozo#\8K6R1C&Ug>cE?'3|kpOzu0RzM'ug{ύcw^͗ԣ\du 2"fa*ÿ.L{'$QYNp7ۛ y)'K&-(N<-|RP0>kI NIVSA'㲊EX?hXq_'N9{R:^+J;&?j+P|Ye![Pt_q ;~~ϟZ" K[z m dʓܞOE}p8nnYvxř?`ۥyi>z[ފNj4hj:6|uep'Аzօ{ɦ' BNVk (!Es1OΈڏ|KnDڕv}'+/  tj˹^LgYqP033U/.vpCQS0ւWs/;_7#VchroM;Tc'0kķ^_4(f] r FV0y8U!~מ+|AqcɱPx,r큹s> 5^֯&p<qձT^r pYԍ\D6RoyZ4]sZ.yMbOn/[{kkx̒#bHI5U` xkmsY#t`FV{qN5mmN֞",x* Z衆- d(P[w ]V){o?_o|pgQAk J:ݏUy(C`(((*YEӵX//{{y*x*A V}'fď*7T6Tiy&dSI$>66u{TfCH*rS-:{;x..hhđ̌0x ~[B76W0)n姻>ٻu>𓐃NWճz?< Batqdj|1/kkT}%Y-'Zm'S_CVN^FMP`G.L<5};z_ebkkIh.du%X{_v{U&XNYX^0ۿd`x#ė6Vs?s\?O> qn]Ye\]VT.WE5eBoR $Dοٯo! ߜ+ZZ5G1_}{eg9"˼g|qß1>1KMn ?\Gk5N_jx~ (-$+x"RI+Di6h?h+ ?1nU=`D)/sb4l,ڞ G@!p oaNZNAX E#x9ఉnivZeh~>OTBޥDR$}#_ݭ~\%Z B2&[<ΧUHϋ<[ķεw꺔qwwu)k1U,$_M"-..-4WWApB tsjE+?%VG,EiRU1]Ei)wg I>k2Ē)_i6k0#ձޟiܱХ8υEHX s#_Ư_7kL;_pLEA>+3 ( (>o8k W#?ᯇlƟg7XX~њ¯x^ԴmB1-k%JįeZ}藲Jq7+{d{_k8jRο'?>\;|ΆqM{/Cfb_=3 WyZ~'E'ʜEF+l$r_OwO2`$\I)a\O8OsSu߼g>WgEgQEQEOM –ZJɡ^RB5k_yJר~s=kAjǟKN?_'<=?V~p&' (h ( ( ( )K+টd>6/|5׊nGwß4+:?e9߇?4iW~_Rgݑ8H+; ( (?9ج?z8N++>+"__G_CT(P(((((((((((()yj?G-~WoR-/ZүԸ/_???EWaEPEPEPhxcQ|'B[o3n/z݌=3_Ó?Uم1dZK>Ox$ SoC:wQ^e6o|cv>8DRU&=9~ O-:iF*%dޝŠ(:Š(((((]k?xSRu ZK;r)V5E4wDTpz5| DXY<&kS|#hnd&?{&G鍧xj+Օע#/ o&,~YuU|Y)ktQEy݅Q@Q@Q@Q@Q@UE״߳ʻaլ~up@<_K=ׇR?i Sf]/P?̹>PO0]Zqy[OOZ5/fkCޥ-guay$14RF} TۿiNx2YܼlsßlE#\Fo}i2\lw$m;PGA_CKhIZW~ s5Oib4愿eF~-hH&ppxw^|f&CG ;mGWz3I[zN ?goâxZ16(2Ti?ΈUo,E#h]eTQoBן:αvwNzI.'п^e:<[{<+s\zW_ 곡ϛKso,o`i/GV!G3̤cZ+u%7)~hG{V4xq;v=p=w/ڄ~?1uA[Ϯ\Яx[LvZFamb-ʾ~?G%[6_e{ٹ?'ᡥWG! yҁ{$,SQE|)˚N > E$K@*N((((((+89m"x'CHE#H<Gs|:zǀgyHm.\sxQ,}Erc0|T91M[><;O)u/)E2^5Oq&cH'[CShTldc"WϬ[`=3|*cY;c9/=_|-KyK5y K+y׃|&9~ J70?ҏ~Pk#{W_o>g úzM2Gr']n MQ/M_.}ɰGFNv3k?%e O~"[j;i̗Z럺HPw%PW*Ph< M" <˻i瓀NH+诲rL& ^}W/qϊGr̫Z=/Uv995EW~nQEQEQEQEQEQExi]e3Bk!4-xTʮ`:W; kKkDBYRIOݻh_Wa7b.̲LNߪ=`:&\NGǾ#~>*~;K[28¼?OagKVݸiS]?btҽ )gR;;ctֽ7S,/|!}tzz. |ة$~w?JEH\=WwtOR^Gg %y&3ÍWRD6+a8aWQ_iQCЊ?xsLٵyU^I%QEtQEQEQEQEQE[Zֳ^\bw)\>}.`.CdԵٵu X.#'9.WtW0xZڌm/Wg\M_;rB:mc+?5 ( (8|{9|U?[OW[vR|,~U |!AmWQ[GZ+2izUb07"j |!AmWM–PDv(U*3RfnX:od(D((((((((+W ww-g00}LaU^,; kVe!&5~9"aqܪשb}.-?'- b)A^t״5|yKV O)$f5z| /R얖wL.G|# 4zþ"6>NR%NR#Adޖ2?Ѡ((+-?#_cBk־?'Pz%'{ / _?( W5yOxz~S"LO}"QE|QEQEQESO2ۏWWM?|mn?_m]y?/^:k0܏z?e9߇?4iWpu~?sh?*."pґIEW'vQEQE~?_sX\_Ekqobpͱ.bmd VAO36_1ޗ/EPL' VAOoK_UFhL'/T?*?#a 4UFh}ei?*?#a 4r2UJBi9_`}*%Zgl?!?ƏJB{z_̾C36G%Zgl?!?ƎW=/_y~ VAO36G+ޗ/QZEZKȲ2F`ETL' VAOI9/7™~|l/m/;v$ѲƸG |gi̺KdV"X1X}"u~=5שq@\ޏܚO3 |g<;u,MCE$*kO#ؼ!/^}Ag ayjdppѱ' L'WG(| x a$$ך]K_UFhL'כz_̾C36G%Zgl?!?ƎW=/_yM –Z?kWEp^Z'} a&AJ2∸Z|aEZaK_rJkfc+u5 VAO'un߫?S9TrLJȗi?*?#a 5\ 2UJBi9_`}*%Zgl?!?ƏJB{z_̾C36G%Zgl?!?ƎW=/_y~ i&CoqjJBx__c>ɳҦ[s]ǚz|?jt/o $UwE|njj~bá~+DŽa' [~<% ?~Gnj%ڟ~;I_K>ۑiIZJɡR5kϓ*<'`2rF^r^]5t iFubqoF~b q_Cá~+DŽa'4|aEZa:kjf}ǃK\П*啴O~bá~+DŽa' [~<% ?~^7nj?_W?jt/o $UwE3j~bá~+DŽa' [~<% ?~Gnj%ڟ_/IƨBV O5_tQ<_y':xK58 gx[ͥ^W-oIO*DSu=3_SO2ۏWF>T rKndؼuiJIjwGjxm!}_Cۙ[lbIdXq ˮYscFqWUD#xWRSiJ)6?_/IƨBV O5_tWx/_y':xK?п_0Wx/?_W?jt/o $UwE3j~bá~+DŽa' [~<% ?~Gnj%ڟ_/IƨBV O5_tQ<_y':xK?п_0Wx/?_W?jt/o $UwE3j~bá~+DŽa' [~<% ?~Gnj%ڟ_/IƨBV O5_tQ<_y':xK?п_0Wx/?_W?jt/o $UwE3j~bá~+DŽa' [~<% ?~Gnj%ڟ_/IƨBV O5_tQ<_y':xK?п_0Wx/?_W?jt/o $UwE3j~bá~+DŽa' [~<% ?~Gnj%ڟ_/IƨBV O5_tQ<_y':xK?п_0Wx/?_W?jt/o $UwE3j~bá~+DŽa' [~<% ?~Gnj%ڟ&|x t.Mql[ikBZF|!.~Q4WTW,Do:aBh*lH(>((((((((((((((((((((((((((((((((((((((((((((((((((((((((((=??U[ς׫ x[HV!=<,r+\<{=)u-:Y({DSz.Jn q| A[=qwg}Kĺn/.Hw7,9 $͒zd_eW ׍)xW¾hoz! GzgG5R1iF7d˳_ 8{5f9T[]s4][j㶃q2L!_#MW^n M"Vo̰ hʶ/_C Ww:7? Ϩ5ͤ{.ʾ[LN=x'w|e,C/5yŒуt>#=(̲Ѱ$rܰ<[t/{$lu{6֖_sq#wVk>(((((((((+ ox/C+4E%?Frʡ0c?Vڥ/wvkzxcn!,]kڜ7R4)җ)5@ñ/G$ŴԱ/iٱyػ۹x# ZLIN37knI_%)rm1n&ӮAAp85vQEQEQEof?xKSFuOm&9| wi}ペ?+?ඩyt]޵[{y#s<|);jZ=ԍ,!YK3IMoAʜQnp4: BVM;yٞǏ 坜N3)+i__NwZVayuuuiQGp6ϵ|E{<Ŵj<+FPJOWwuohu _4[ 0p RT22w__SxNap6KZj1g(1džҳYͭꨇo'웠<%~dFmħPR1rBt&ͿOxŬu}.M1!AAе kvu=a2\[\%D!Շ zWo m?g~[ ߁jv&Gb݃l4݉ZKZlE!A$j9,z}p+Կ_ރx@𽇍a^..5x.s'FW_>%7ճ/r->Ow_SstSž1-#Yiq NƐwݺbwᾳ':2Ovxp} ((*hEexv.ǧ PdwGRGTתp6>V9H]k [E?5ƳX/&.'I<ř؞I$OV+doo^8i~ H{Cw=ͱe=;$9s6Y.|dеhe`{\W⇍_k_ԗuGbqx0nh&>tNR)ʊZ(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((  (̷mz*I`w>"eߴƒ̓|X~8x:?%4Ilx+-+1 }@~ >|7m֘S>SqpW'>߭J~zVKVsy@WZ ~iQ_z|c OO%.Ziګtk;,sH61 \,eaOV 3߀߶\=TyFuMObf*&cP\?t_ qKf~3e9?8 qnL"9SQ~˗? _[OJڔvY#+%A x $ >5_~Ս+}:"; *n> $7_Bf'?,>$r KtRȧ3۲%+oSA>'i6Oǂ5#T{~5$R_R8=:+W_ Ix~ٲ`'aqTA4s>//M𗄴u=gS}BK#tHrXW/ď .An/tҁz ĒpU[ ^񭇅 ]qp†* H$03_˽OS5C$1;1I$\'߅<3ϊ56`($9ܟݱ1C涵]sX i쯬f{{y),!*y  Њ~{/SK>@91]F~2FpGЂt?O:[K33 L\J+sG8=O.HFI""z /MLXAjTT*\8~ןw1DŽ<su3uvuF۪(Š(<|1!}}m-5T>lİ>I__|nɥkՒB%D(hڃݰ?mdw7xGXY-ML&hI`>+B|l?E 3h}5IQ3 䝙Tۊ_3.ρ,e[GtGF:apZ\JSv}Tfԣ8ͪͻQ\'i*^+i$e7WIwO𦞬oI˖Eʯa%L޿v:)4'O]'o4븎 Z.㏍ZG^ q%=ڣ݈$WO!m u/h {(H<1i8Id;U}R2IZxwH`1PFEQP4T6I$'/]υ<]f[;y֗p:tD0CAz) $?e}R&>BZ-gHiv'7e c$9|F N7 y/qcSW܎CHGI*" _!Y>'lOn6H\h/^~:sz8OV}C| ٻ᎝ɦjNK#uyI 袠(((j?W独wdaA%#dOT[#ڃq>I˖Eʯa%L޿v:)4'O]'o4븎 Z.㏍ZG^ q%=ڣ݈$WO!m u/h {(H<1i8Id;U}R2IZxwH`1PFEQP4T6I$QE!Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@%w002&6FVfv2(&6FVfv&6FVfv&6FVfv&6FVfv&6FVfv&6FVfv8XV~ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@6666_HmH nH sH tH V`V nNormal d$CJOJPJQJ_HaJmH sH tH DA D Default Paragraph FontRiR  Table Normal4 l4a (k (No List j@j !\# List Paragraph,Bulleted list & Fm$OJQJ@U`@ n Hyperlink7>*B* S*Y(phi4@4 nHeader  !4 @"4 nFooter  !B' 1B * 0Comment ReferenceCJaJ<B< * 0 Comment TextCJaJJ/QJ * 0Comment Text CharOJPJQJtH @jAB@ * Comment Subject5\V/qV * Comment Subject Char5OJPJQJ\tH RR * Balloon Text dCJOJQJ^JaJV/V * Balloon Text CharCJOJPJQJ^JaJtH P P:0Revision$CJOJPJQJ_HaJmH sH tH x/x t0Style (Latin) Arial 11 pt Char$CJOJPJQJ^JaJmH sH tH tt t0Style (Latin) Arial 11 ptd((OJPJQJ^JmH sH \ \  7 No Spacing ^$CJOJPJQJ_HaJmH sH tH *W`* 5HuStrong5\RJR  5HuSubtitle$<@&a$CJOJPJQJ^JaJN/N 5Hu Subtitle CharCJOJPJQJ^JaJtH |/| \# &List Paragraph Char,Bulleted list CharCJOJPJQJaJtH ^/#^ E TableGrid :V"4" CJOJQJ_HaJmH sH tH b/2b Default #7$8$H$-B*CJOJQJ^J_HaJmH phsH tH FV AF %yjFollowedHyperlink >*B*phOrPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭VGRU1a$N% ʣꂣKЛjVkUDRKQj/dR*SxMPsʧJ5$4vq^WCʽ D{>̳`3REB=꽻Ut Qy@֐\.X7<:+& 0h @>nƭBVqu ѡ{5kP?O&Cנ Aw0kPo۵(h[5($=CVs]mY2zw`nKDC]j%KXK 'P@$I=Y%C%gx'$!V(ekڤք'Qt!x7xbJ7 o߼W_y|nʒ;Fido/_1z/L?>o_;9:33`=—S,FĔ觑@)R8elmEv|!ո/,Ә%qh|'1:`ij.̳u'k CZ^WcK0'E8S߱sˮdΙ`K}A"NșM1I/AeހQתGF@A~eh-QR9C 5 ~d"9 0exp<^!͸~J7䒜t L䈝c\)Ic8E&]Sf~@Aw?'r3Ȱ&2@7k}̬naWJ}N1XGVh`L%Z`=`VKb*X=z%"sI<&n| .qc:?7/N<Z*`]u-]e|aѸ¾|mH{m3CԚ .ÕnAr)[;-ݑ$$`:Ʊ>NVl%kv:Ns _OuCX=mO4m's߸d|0n;pt2e}:zOrgI( 'B='8\L`"Ǚ 4F+8JI$rՑVLvVxNN";fVYx-,JfV<+k>hP!aLfh:HHX WQXt,:JU{,Z BpB)sֻڙӇiE4(=U\.O. +x"aMB[F7x"ytѫиK-zz>F>75eo5C9Z%c7ܼ%6M2ˊ 9B" N "1(IzZ~>Yr]H+9pd\4n(Kg\V$=]B,lוDA=eX)Ly5ot e㈮bW3gp : j$/g*QjZTa!e9#i5*j5ö fE`514g{7vnO(^ ,j~V9;kvv"adV݊oTAn7jah+y^@ARhW.GMuO "/e5[s󿬅`Z'WfPt~f}kA'0z|>ܙ|Uw{@՘tAm'`4T֠2j ۣhvWwA9 ZNU+Awvhv36V`^PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!g theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] D b4 4__O  [D]W :3"!R$<&'*-/14 89;<?D@CFaH1LOTTX\^|`a?c efghjj689:;=?@BCDEFGIJKLMNOPRSTUVWXYZ[\^_`abcdefhikln ,H/He/gij7<>AHQ]gjmWLLLbX-0 +-2X[!!! /XR$>FDދ^U2GhR$^1$w*Z#j@ (    s >A?"Picture 3#" `?  s >A?"Picture 3#" `?  s >A?"Picture 3#" `?B(    s >A?"Picture 3#" `?  S <A Rossini 2 Logo#" `?B S  ?D b lt tO-t-t-t _Hlt95664783 _Hlt95664784 _Hlk524220602LLQb@@LLTb \\^^^^^^^^^bb] _ """=.^^^^^^^^^^/___T`aabb33333Z[^^&&cc==@@HHQQ? ? W W ddXXm%m%_&_&&&''))//;0;0i0i0?3?30606A8A8;;TTTTTTVVVVVVVWWWWW=W=WkWkWzW}WWWWW![!["["[D\D\ ] ]]]]]]]]]_^_^^^^^^^____```aNbsbwbbbbZ[^^&&cc==@@HHQQ? ? W W ddXXm%m%_&_&&&''))//;0;0i0i0?3?30606A8A8;;TTTTTTVVVVVVVWWWWW=W=WkWkWzW}WWWWW![!["["[D\D\ ] ]]]]]]]]]_^_^^^^^^^^^^^^^____```aNbsbwbbbb=o B\H^LL$R`lxB ZؐP&+&\a)t10Dɸ12n1$ ">&+goVK>-EizN⣬*R= 3MU*l6W*<%W^դhuc]Ce\j҂baqz8sʸTu vhVK^K`OJPJQJ^Jo(-^`OJQJ^Jo(hHo^`OJ QJ o(hH ^ `OJQJo(hH ^ `OJQJ^Jo(hHo[^[`OJ QJ o(hH+^+`OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohp^p`OJ QJ o(hHh@ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohP^P`OJ QJ o(hH ^`OJQJo(^`OJQJ^Jo(o p^p`OJ QJ o( @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJ QJ o( ^`OJQJo(^`OJQJ^Jo(o P^P`OJ QJ o(h^`OJQJo(hHh^`OJQJ^Jo(hHohp^p`OJ QJ o(hHh@ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohP^P`OJ QJ o(hHhh^h`OJQJo(hHh8^8`OJQJ^Jo(hHoh^`OJ QJ o(hHh ^ `OJQJo(hHh ^ `OJQJ^Jo(hHohx^x`OJ QJ o(hHhH^H`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHhh^h`OJQJo(hHh8^8`OJQJ^Jo(hHoh^`OJ QJ o(hHh ^ `OJQJo(hHh ^ `OJQJ^Jo(hHohx^x`OJ QJ o(hHhH^H`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHhp^p`OJQJ^Jo(hHoh@ ^@ `OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHhP^P`OJQJ^Jo(hHoh ^ `OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohp^p`OJ QJ o(hHh@ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohP^P`OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohp^p`OJ QJ o(hHh@ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohP^P`OJ QJ o(hH^`o(. ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH.h^`OJQJo(hHh^`OJQJo(hH p^p`OJ QJ o( @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJ QJ o( ^`OJQJo(^`OJQJ^Jo(o P^P`OJ QJ o(h^^^`OJQJo(hHh.^.`OJQJ^Jo(hHoh^`OJ QJ o(hHh ^ `OJQJo(hHh^`OJQJ^Jo(hHohn^n`OJ QJ o(hHh>^>`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hH ^`OJQJo(^`OJQJ^Jo(o p^p`OJ QJ o( @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJ QJ o( ^`OJQJo(^`OJQJ^Jo(o P^P`OJ QJ o(hh^h`OJQJo(hHh8^8`OJQJ^Jo(hHoh^`OJ QJ o(hHh ^ `OJQJo(hHh ^ `OJQJ^Jo(hHohx^x`OJ QJ o(hHhH^H`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh ^`hH.h ^`hH.h pL^p`LhH.h @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PL^P`LhH.hhh^h`5OJQJ^Jo(hH.88^8`.L^`L.  ^ `.  ^ `.xLx^x`L.HH^H`.^`.L^`L.h^`OJQJo(hHh^`OJQJ^Jo(hHohp^p`OJ QJ o(hHh@ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohP^P`OJ QJ o(hHh^`OJQJo(hHhp^p`OJQJ^Jo(hHoh@ ^@ `OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHhP^P`OJQJ^Jo(hHoh ^ `OJ QJ o(hH ^`OJQJo(^`OJQJ^Jo(o p^p`OJ QJ o( @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJ QJ o( ^`OJQJo(^`OJQJ^Jo(o P^P`OJ QJ o(h^`OJQJo(hHh^`OJQJ^Jo(hHohp^p`OJ QJ o(hHh@ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohP^P`OJ QJ o(hH8^8`OJPJQJ^Jo(-^`OJQJ^Jo(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJQJ^Jo(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJPJQJ^Jo(-^`OJQJ^Jo(hHo^`OJ QJ o(hH ^ `OJQJo(hHR^R`OJQJ^Jo(hHo"^"`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJPJQJ^Jo(-^`OJQJ^Jo(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJ QJ o(hHh^`OJQJ^Jo(hHohp^p`OJQJ^Jo(hHoh@ ^@ `OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHhP^P`OJQJ^Jo(hHoh ^ `OJ QJ o(hH2n1Ce 3MU^huc+&=oa)6W j*RizNgoVKt108su v%W$RP&">baqT)`                 @ J^t-:0f 2yo                           VsF                                                                                #v                          bHM F(Gn}: ʺ-6DNX~_/         d(֯         6%                         e +n_ psr$FVlDz U`}0<0@PinE / 6 ?S X GQ s   E C:=j2:hZz: 4Sp2  Q (?QIR1wW 8!4"X#5#T#|#$@9$%&%W&T#&#.&XN&T&Yn&r1':B' J'nw'5* V+ u, O-Y...r.k/X1N2x54556m36We6y6 7bY78 < b<HK>3?r%A&0nչ}&#B<Ng-NCHNfO QOaaP&P Q/QUR T&TUJVYVTrV@kWXm>Vw-7:=۳%?~l~&2r+_+J:[[j|}e"(M(Sxqs2Q)6*0"2D+:C&ncxy9[gW>iFW->LY ZTe)U\Z v&pDn|%,^LU9YCi a('-5?JX>knIK2j2^DmCN}cXy p1ifJsK%#V# La9f 'GI=(dn.<zS:OP_Ao:^OY* AHctN;1\#/3afqtNh^*35Etk~XU|41oXhr8E$*]t>@Lrsa#f}%EQh)kcyyc* C,+7]S^^@  b@Unknown G.[x Times New Roman5Symbol3. .[x Arial5. .[`)Tahoma7..{$ Calibri9. . Segoe UI7$BCambriaC.,.{$ Calibri Light?= .Cx Courier New;WingdingsA$BCambria Math"qh{grҧG,g P 0 P 0!50v^v^ 3qHP ?On2! xxG & IROSSINI  Reduction of Surgical Site Infection using a Novel Interventiongrayzb-Kayley King (Birmingham Clinical Trials Unit)l                   Oh+'0$ \h    LROSSINI Reduction of Surgical Site Infection using a Novel InterventiongrayzbNormal0Kayley King (Birmingham Clinical Trials Unit)7Microsoft Office Word@q@,MUk@dĀ@[̠  P ՜.+,D՜.+,H hp  *University Of Birmingham0v^ JROSSINI Reduction of Surgical Site Infection using a Novel Intervention Title 8@ _PID_HLINKSAe%/http://www.birmingham.ac.uk/privacy/indec.aspx  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry Fb#̠@1Table}WordDocument MSummaryInformation(DocumentSummaryInformation8MsoDataStoren ̠0 ̠ZBVYEGMP0Y4MX==2n ̠0 ̠Item 2PropertiesUCompObj r   F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q